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Abstract
The aim of the research documented in this thesis was to investigate molecular imag-
ing using a MARS spectral scanner. This scanner is a photon-counting computed
tomography (CT) system that simultaneously measures 5-8 energies. It operates
in the clinical diagnostic energy range (30-120 keV) and at high spatial resolution
(50-200 µm). The technique enables differentiation of multiple high atomic number
(high-Z) materials and human tissues (calcium and water) from data obtained in a
single exposure.
Four potential clinical applications were investigated. In each application, a high-
Z pharmaceutical was used to identify and quantify disease-related tissue. They
were: (1) iodine, a clinically available contrast, was used to segment healthy and
disease-related tissue in an ex-vivo lung mouse model of chronic tuberculosis. Lung
segmentation was validated using micro-CT. (2) Gold nanoparticles functionalised
with monoclonal antibodies were used to target two different cancer cell types (breast
and lymphoma) in a cross-over study. Compared to the control nanoparticles, uptake
of gold nanoparticles targeted to specific cancer cells increased five-fold, demonstrat-
ing highly specific and quantitative molecular imaging. (3) Hafnia (hafnium oxide)
nanoparticles targeted to bone microcracks were investigated in ex-vivo and murine
models. An increase in accumulation of the targeted hafnia nanoparticles compared
to the non-targeted nanoparticles was observed. (4) Hafnia nanoparticles packed
inside probiotics were imaged within the gastrointestinal (GI) tract in-vivo. A key
finding was that the bio-functionalised hafnia nanoparticles withstood the harsh en-
vironment of the GI tract, thus, have the potential to be used as a patient-friendly,
orally delivered contrast. In summary, spectral photon-counting CT for quantitative
molecular imaging was shown to be feasible using MARS scanners. MARS imaging
was able to assess pathology at high resolution and evaluate novel nanoparticle-based
contrast agents and delivery of anti-cancer drugs. Targeted nanoparticle contrast
provides highly specific three-dimensional imaging of various diseases. In addition,
quantifying drug delivery could provide a means to accelerate the development of
new drug therapies, for example, for infectious disease and cancer. More precise
diagnosis, monitoring of therapy efficacy, and the development of new and more
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CSM Charge summing mode
CT Computed tomography
CZT Cadmium zinc telluride
DICOM Digital imaging and communications in
medicine
ELISA Enzyme linked immunosorbent assay
EPR Enhanced permeability and retention
ERF Edge response function
FOV Field of view
HA Hydroxyapatite





keV Kilo electron volt
kVp Kilovolt peak
µ Linear attenuation coefficient
MD Material decomposition
Medipix3RX Current photon-counting detector chip
MRI Magnetic resonance imaging
MTF Modulated transfer function
NIST National Institute of Standards and
Technology
NTA Nitrilotriacetic acid
PET Positron emission topography
PMMA Polymethylmethacrylate
QA Quality assurance
SKBR3 HER2 positive human breast cancer cell
line
SNR Signal-to-noise ratio
SPM Single pixel mode
TB Mycobacterium tuberculosis
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Particular terms used frequently throughout my work and in relation to spectral
photon-counting CT are outlined:
Term Definition
Basis function A basis function is an element of a particular set of vec-
tors for a set of functions. A linear combination of basis




Bremsstrahlung radiation is produced by electrons high in
kinetic energy interacting with the nucleus of a target atom.
Chelating agent Chelating agents are chemical compounds that are capable
of forming bonds with metal ions.
Ex-vivo Ex-vivo defines a process that is performed outside a living
organism.
Functionalisation Functionalisation of nanoparticles refers to the addition of
a molecule so that the nanoparticle can perform a specific
action. For example, tumour targeting with an antibody
molecule.
Histology Histology refers to the study of microscopic structures, typi-
cally using microscopy. Sectioning (and sometimes destruc-
tion) of tissue is often required for this technique.
Linear attenua-
tion (µ)
Beer Lambert’s law; I = Ioe
−µx, describes the measured
intensity (I) of radiation as it passes through tissue. Io
is the incident radiation, µ is the linear attenuation coef-
ficient, and x is the distance through the tissue. µ can
be represented by the sum of cross-sections for each X-ray
interaction (Rayleigh, photoelectric, Compton), or as the




Linear attenuation is converted to HU for the purpose of
normalising image intensity with respect to water by the




HU of water, air, and bone are defined as 0, -1000, and
+1000 HU, respectively.
In-vivo In-vivo defines a process that is performed inside a living
organism.
In-vitro In-vitro defines a process taking place within a test tube or
culture dish, normally at a cellular level.
K-edge The K-edge of an element/atom is the binding energy of an
innermost electron (K-shell electron).
Mass attenuation
coefficient
The mass attenuation coefficient is used to characterise an
absorbing material as it provides information about the fun-
damental properties of the matter in which the X-ray is pa-
xxi
ssing through. The mass attenuation coefficient is defined
as (µ/ρ), the ratio of the linear attenuation coefficient and
density. The mass attenuation coefficient is both material
and energy dependant, with units cm2g−1.
Nanotechnology Science of materials in the range of 1-100 nm in diameter is
referred to as nanotechnology.
Phantom In the current thesis, custom made phantoms are precisely
machined objects made of known materials. A phantom is
scanned in order to test and/or calibrate the MARS scan-
ner. The calibration phantom always includes a water vial
as water closely approximates the radiation absorption and
scattering properties of muscle and soft tissues.
Pixel Pixel refers to one element on an X-ray detector.
Polychromatic A polychromatic X-ray beam consists of a spectrum of ra-
diation wavelengths.
Projections Projections refer to the X-ray images acquired during a scan
to provide 3D information. For example, 720 projections
means 720 X-ray images were taken over 360o, or one X-ray
image per 0.5o.
Slice The final output of the reconstruction chain is a series of
two-dimensional (2D) images in Digital Imaging and Com-
munications in Medicine (DICOM) format, which makes
up the three-dimensional (3D) information about the ob-
ject scanned. A single 2D image from the stack of DICOM
images is referred to as a slice.
Voxel Voxel is the 3D volume represented by reconstructed data.
An isotropic voxel size is equal in all directions and can be
made small to increase resolution.
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Academic Contribution
The aim of the current thesis was to contribute to the development and advance-
ment of spectral photon-counting imaging. The first spectral images of a human
were taken by the large-bore MARS scanner and presented in July 2018 (Web ar-
ticle: First-ever colour X-ray on a human). Achieving spectral images of humans
reflect the translational possibilities of the present work. Contributions from the
current thesis to academia and the successful development of imaging with MARS
scanners are outlined in the following awards, conferences, and publications.
The MARS collaboration indicates a direct and indirect contribution due
to my research. Overall, my contribution has included assisting students in using
the scanner; providing user manuals for analysing energy data; and testing in-house




1. Ostadhossein, F., Tripathi, I., Benig, L., LoBato, D., Moghiseh, M., Lowe, C.,
... & Chernoglazov, A. (2020). Multi ’color’ delineation of bone micro-damages
using ligand directed hafnia nanodots and photon-counting K-edge CT imag-
ing. Advanced Functional Materials, 30 (4) 1904936, doi: 10.1002/adfm.201904936,
2019.
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The study examined non-invasive assessment of bone microdamage with tar-
geted hafnia (HfO2) nanoparticle (HfNPs) in an excised human phalanx bone
and in-vivo murine specimens using MARS scanners. Results of the study
showed material differentiation between HfNPs, lipid, HA (bone-like), water
(soft tissue like), and background for ex-vivo and in-vivo studies. Quantifica-
tion of non-targeted and targeted HfNPs in rat specimens was achieved: higher
concentration of HfNPs was present in the limb containing microdamage. I
contributed the study design, data collection and analysis, and write up of a
detailed written report. My report is included in the accepted manuscript.
2. #Moghiseh, #M., Lowe, C., Lewis, J. G., Kumar, D., Butler, A., Anderson,
N., & Raja, A. (2018). Spectral photon-counting molecular imaging for quan-
tification of monoclonal antibody-conjugated gold nanoparticles targeted to
lymphoma and breast cancer: an in-vitro study. Contrast Media & Molecular
Imaging, 2018, doi: 10.1155/2018/2136840. # Authors of equal contribution.
The proof-of-concept study examined the utility of non-invasive spectral photon-
counting CT for measuring gold labelled monoclonal antibodies targeted to spe-
cific cancer cells. Results showed that Raji cells and HER2 positive SKBR3
breast cancer cells take up AuNPs if they are exposed to a monoclonal antibody
specific to them, demonstrating the potential to detect tumour heterogeneity.
My contribution to the study included data collection and processing, analysis
and interpretation, and write up of the first manuscript draft. Furthermore, I
am corresponding author of the published manuscript.
3. Marfo, E., Anderson, N. G., Butler, A. P., Schleich, N., Carbonez, P., Damet,
J., Lowe, C., ... & Raja, A. Y. (2020). Assessment of material identification
errors, image quality and radiation doses using small animal spectral photon-
counting CT. IEEE Transactions on Radiation and Plasma Medical Sciences.
xxiv
The interplay between material identification errors, image quality indicators,
and radiation doses for MARS small-bore research scanner were investigated.
Custom made Perspex phantoms and mice with thermoluminescent dosimeters
(TLDs) inserted were used in the current study. My contribution included
acquiring and analysing data obtained from the Perspex phantoms.
4. Ostadhossein, F., Nelappana, M., Lowe, C., Moghiseh, M., Butler, A., de
Ruiter, N., Mandalika, H., Tripathi, I., Misra, S. K., & Pan, D. Hitchhiking
probiotic vectors to deliver ultra-small hafnia nanoparticles for ’color’ gas-
trointestinal tract photon-counting X-ray imaging. Submitted to Angewandte
Chemie, 2020.
HfNPs included in probiotic yoghurt as a means of delivering GI tract contrast
was imaged using the MARS scanner. I contributed to the study by performing
MARS scans, analysis, and writing the results for the manuscript. Further-
more, I performed surgery on the mice by inserting TLDs post mortem.
Manuscript in preparation
1. Lowe, C., Ortega-Gil, A., Moghiseh, M., Anderson, N., Butler, A., Vaquero,
J. J., & Raja, A. Characterisation of pulmonary tuberculosis in excised mouse
lungs by quantifying iodine uptake using MARS photon-counting CT imaging.
The MARS scanner was employed to characterise TB infected lung tissue by
quantifying iodine uptake. SuperArgus micro-CT subsystem was used for vali-
dation and histology will be used to enhance our understanding for lung tissue
segmentation. Moreover, silver nitrate was used to show enhancement of soft
tissue can be achieved by multiple contrasts, and imaged simultaneously using
the MARS scanner. I contributed to study design, data acquisition and anal-
ysis, interpretation of the results, and write up of the first manuscript draft.
The requirement of automatic segmentation tools for this study has meant I
have collaborated with the HIT Lab at the University of Canterbury to develop
and integrate such a tool in MARS Vision for future users.
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2. Kumar, D., Moghiseh, M., Chitcholtan, K., Lowe, L., & Raja, A. Assessment
of ovarian cancer by quantifying targeted gold nanoparticle contrast using
MARS imaging.
My contribution to this study includes acquisition and analysis of MARS data
for post mortem imaging of mice with ovarian cancer and injected gold nanopar-
ticles. I also prepared in-vivo tissue samples for inductively-coupled plasma
(ICP) and microscopy examination. I performed bright and dark-field mi-
croscopy. ICP and microscopy results will be included in the manuscript in
preparation.
Book chapters
1. Kumar, P., Singh, B., Chaudhari, P., Jose, J., Butler, A., Prebble, H., Moghiseh,
M., & the MARS Collaboration. (2019). Preclinical non-invasive imag-
ing in cancer research and drug discovery: An overview. In K. Bose & P.
Chaudhari (Eds.), Unravelling cancer signaling pathways: A multidisciplinary
approach. (pp. 419-469). Singapore: Springer Nature, doi: 10.1007/978-981-
32-9816-3-17.
2. Raja, A., & the MARS collaboration. Spectral CT imaging using MARS
scanners. In Ken Taguchi, Ira Blevis, and Kris Iniewski (Eds.), Spectral com-
puted tomography: technology and applications. ISBN 978-1-138-59812-6.
Publication scheduled for April, 2020 by CRC Press.
Peer reviewed conference proceeding/paper
1. Mahdieh Moghiseh, Dhiraj Kumar, Aamir Raja, Chiara Lowe and the MARS
collaboration. Functionalised nanoparticles for ovarian cancer targeting and
MARS spectral imaging. European Congress of Radiology (ECR), February
27March 3 2019, Vienna, Austria.
Presented in this conference record: spectral CT imaging of gold nanoparticles
targeted to specific cancer cells in-vitro and in-vivo.
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2. Chiara Lowe, Ana Ortega and the MARS Collaboration. MARS pulmonary
spectral molecular imaging: potential for locating tuberculosis involvement.
IEEE Nuclear Science Symposium and Medical Imaging Conference, Sydney,
Australia, November 2018.
This published conference record presented non-invasive high resolution spectral
photon-counting CT imaging of tuberculosis infected pulmonary tissue using
standard iodine contrast material. I performed scans, quantitative analysis,
and wrote the conference record.
3. Mahdieh Moghiseh, Dhiraj Kumar, Aamir Raja, Peter Sykes, Chiara Lowe.
Influence of gold nanoparticle size on uptake into different ovarian cancer cell
lines measured by spectral photon-counting CT. Biomaterials, 2018.
Different sized metal nanoparticles were synthesised and functionalised with
targeting ligand molecules and PEG. The goal of the study was to test toxicity
and, using the MARS scanner, image the targeting ability under in-vitro con-
ditions. I contributed to the design of the MARS scanning protocol, performed
scans and analysis.
4. Fatemeh Asghariomabad et al. [includes Chiara Lowe]. Intrinsic respiratory
gating for MARS imaging, IEEE Nuclear Science Symposium and Medical
Imaging Conference, Sydney, Australia, November 2018.
5. Emily Searle et al. [includes Chiara Lowe]. Distinguishing iron and calcium
using MARS spectral CT, IEEE Nuclear Science Symposium and Medical
Imaging Conference, Sydney, Australia, November 2018.
doi:10.1109/NSSMIC.2018.8824671
6. Mahdieh Moghiseh et al. [includes Chiara Lowe]. Cancer imaging with
nanoparticles using MARS spectral scanner, IEEE Nuclear Science Symposium
and Medical Imaging Conference, Sydney, Australia, 2018.
doi:10.1109/NSSMIC.2018.8824632.
7. Anthony Butler et al. [includes Chiara Lowe] First living human images from
a MARS photon-counting 8-energy CT, IEEE Nuclear Science Symposium and
Medical Imaging Conference, Sydney, Australia, November 2018.
xxvii
8. Mahdieh Moghiseh et al. [includes Chiara Lowe]. Spectral CT of cancer
cells with nano-particles: in-vitro and in-vivo results, Radiological Society of
North America (RSNA), Chicago, America, November 2018.
9. Emmanuel Marfo, Pierre Carbonez, Jérôme Damet, Chiara Lowe, Nigel An-
derson, Nanette Schleich, Aamir Raja, and Anthony Butler. In-vivo dosimetry
with the small animal MARS multi-energy CT. Engineering and the Physical
Sciences in Medicine Conference, EPSM, Australia 2017.
TLDs were placed within mice for MARS research scanner dosimetry. I per-
formed surgery on the mice post mortem, MARS scans, and analysis.
Published abstracts
1. Chiara Lowe, Fatemeh Ostadhossein, Mahdieh Moghiseh, Marzieh Anjom-
rouz, Raj K Panta, Aamir Y Raja, Anthony P H Butler, and Dipanjan Pan.
Functionalised nanoparticles for bone micro-fractures with spectral photon-
counting CT. Accepted for publication to European Society of Radiology
(ECR), Vienna, Austria, 2020.
Visualisation of bone microdamage with functionalised nanoparticles in ex-
cised human phalanx and whole rat specimens was achieved. Spectral photon-
counting CT using a MARS scanner allowed characterisation of bone micro-
damage, microarchitecture, mineralisation, and composition. Such character-
isation is essential to assess bone quality and the toughening mechanism of
bone
2. Yann Sayous, Maya R Amma, Ilaria Bernabei, Anais Viry, Nathalie Busso,
Anthony Butler, Lisa Stamp, Fabio Becce, Aamir Y Raja, and the MARS
Collaboration. Quantification of various calcium crystals for gout, pseudo-
gout and other arthropathies using spectral photon-counting CT. Accepted for
publication to European Society of Radiology (ECR), Vienna, Austria, 2020.
The aim of this study was to confirm a method for distinguishing various cal-
cium crystals in a range of arthropathies, in preparation for planned imaging
studies of excised specimens and patients.
xxviii
3. Shishir Dahal, Emily Searle, Steven Gieseg, Aamir Y Raja, Anthony Butler,
and the MARS collaboration. Histology of atherosclerotic plaque com-
pared with tissue components measured using a spectral photon-counting CT.
Accepted for publication to European Society of Radiology (ECR), Vienna,
Austria, 2020.
This study aimed to confirm a method for non-invasively measuring four tissue
components in atherosclerotic plaques. Histology of plaques were compared to
3D quantitative images of fat, water, calcium, and iron generated by a spectral
photon-counting CT.
4. Aysouda Matanaghi, Aamir Raja, Celeste Leary, Maya Rajeswari Amma, Raj
Panta, Marzieh Anjomrouz, Mahdieh Moghiseh, Anthony Butler, Benjamin
Bamford, and the MARS collaboration. Semi-automatic quantitative as-
sessment of site-specific bone health using spectral photon-counting CT. Jour-
nal of Nuclear Medicine, 2019.
5. Aamir Raja, Chiara Lowe and the MARS Collaboration. MARS spectral CT
imaging using CZT-Medipix3RX; 20th International Workshop on Radiation
imaging Detectors (iWoRiD), Sundsvall, June 2018.
The abstract reported on the use of MARS spectral imaging for various in-vitro
and in-vivo studies. I wrote and edited the first draft for submission.
6. Chiara Lowe, Mahdieh Moghiesh, John Lewis, Anthony Butler, Aamir Raja,
Nigel Anderson. Spectral photon-counting CT imaging of gold labelled mon-
oclonal antibody drug delivery to Raji and HER2 positive breast cancer cells
- a phantom study. Society for Biomaterials 2018 SFB, Atlanta, USA.
This abstract was presented as a poster: see item 2 under poster presentations
(below).
Submitted abstracts
1. Fatemeh Ostadhossein, Indu Tripathi, Lily Benig, Mahdieh Moghiseh, Chiara
Lowe, and Dipanjan Pan. Multi-color delineation of bone microdamages using
ligand-directed sub-5 nm hafnia nanodots and photon counting CT imaging.
xxix
Submitted to AlChE Annual Meeting (Topical Conference: Chemical Engi-
neers in Medicine), 2020.
The abstract reported bone microdamage imaging using ligand-directed hafnia
nanoparticles using photon-counting CT. Submitted April, 2020 by Fatemeh




1. Chiara Lowe, and the MARS collaboration. MARS imaging of bone mi-
crofractures with targeted nanoparticles for early risk assessment of osteolysis;
Queenstown Research Week 2019, Medical Devices and Imaging Technologies,
Queenstown, New Zealand September 2019.
This talk presented spectral photon-counting imaging, achieved using the MARS
scanner, of microdamage in phalanx and rat specimen using targeted hafnium
nanoparticles. The clinical problem and context was early risk assessment of
osteolysis; a pathological process triggered by an immunological response that
results in bone around an artificial implant being lost. This talk was awarded
second place for student oral presentations.
2. Chiara Lowe, and the MARS collaboration. Pre-clinical applications for
MARS spectral computed tomography: tales of a third year; Student Re-
search Symposium - Te Wanaka Rakahau - koka 2019, Dunedin, New Zealand
August 2019.
I was able to present my work to local audiences by attending university sym-
posiums, seminars, and open days.
3. Chiara Lowe, Aamir Raja, Mahdieh Moghiseh, Anthony Butler, Ana Ortega.
Pulmonary tuberculosis imaging with MARS spectral CT scanner; MARS
Workshop, Christchurch, New Zealand 8th November, 2018.
Proof of concept study: imaging tuberculosis within mouse lungs using iodine
and silver contrast.
xxx
4. Chiara Lowe, Aamir Raja, Mahdieh Moghiseh, Anthony Butler. MARS spec-
tral molecular imaging with nanoparticles; Postgraduate Symposium, Christchurch,
New Zealand 18th July 2018.
This talk discussed the integration of nanoparticle technology with photon-
counting computed tomography (CT) imaging. Potential clinical applications,
including early diagnosis of cancer and its treatment assessment using MARS
spectral CT scanner were discussed.
5. Chiara Lowe, Aamir Raja, Mahdieh Moghiseh, Anthony Butler. Gold nanopar-
ticles and MARS spectral CT imaging; University of Otago Open Day, Christchurch,
New Zealand 13th November 2017.
6. Chiara Lowe, Aamir Raja, Mahdieh Moghiseh, Anthony Butler. Gold nanopar-
ticles and MARS spectral photon-counting CT (pecha kucha); Dunedin Sem-
inar, Dunedin, New Zealand August 2017.
7. Emmanuel Marfo, Aamir Raja, Chiara Lowe, Pierre Carbonez, Anthony
Butler, Nina Schleich, Nigel Anderson. Gate Monte Carlo dosimetry simula-
tion of MARS spectral CT; Geant4 User Workshop 2017, Wollongong.
Presented by Emmanuel Marfo on behalf of the MARS team.
8. Fatemeh Ostadhossein, Aamir Raja, Chiara Lowe, Mahdieh Moghiseh, An-
thony Butler, Raj Panta, Marzi. Multicolor delineation of bone microdamages
by hafnium nanodots and MARS spectral CT, Biomedical Engineering Society
(BMES) Annual Meeting, Philadelphia, October 16-19, 2019.
Presented by Fatemeh Ostadhossein on behalf of the MARS team.
9. Mahdieh Moghiseh and the MARS collaboration; Cancer imaging with
nanoparticles using MARS spectral scanner, IEEE Nuclear Science Symposium
and Medical Imaging Conference, Sydney, Australia, November 2018.
Presented by Mahdieh Moghiseh on behalf of the MARS team.
10. Anthony Butler and the MARS collaboration; First living human images
from a MARS photon-counting 8-energy CT, IEEE Nuclear Science Sympo-
sium and Medical Imaging Conference, Sydney, Australia, November 2018.
Presented by Anthony Butler on behalf of the MARS team.
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Poster
1. Chiara Lowe, Ana Ortega and the MARS Collaboration. MARS pulmonary
spectral molecular imaging: potential for locating tuberculosis involvement;
2018 IEEE Nuclear Science Symposium and Medical Imaging Conference, Aus-
tralia 11th-17th November 2018, Poster M-14-168.
This poster presented the published conference record, item one (above).
2. Chiara Lowe, Mahdieh Moghiesh, John Lewis, Anthony Butler, Aamir Raja,
Nigel Anderson. Spectral photon-counting CT imaging of gold labelled mono-
clonal antibody drug delivery to Raji and HER2 positive breast cancer cells -
a phantom study; Society for Biomaterials 2018 SFB, Atlanta, USA 11th-14th
April 2018, (Poster #673).
This poster demonstrated non-invasive spectral photon-counting CT, with func-
tionalised AuNPs, can differentiate between HER2 positive (SKBR3) and neg-
ative (Raji) tumour cell lines at clinical X-ray energy ranges using cross-over
experiments with cell specific monoclonal antibodies.
3. Mahdieh Moghiesh, Dhiraj Kumar, Aamir Raja, Peter Sykes, Chiara Lowe.
Influence of gold nanoparticle size on uptake into different ovarian cancer cell
lines measured by spectral photon-counting CT; Society for Biomaterials 2018
SFB, Atlanta, USA 11th-14th April 2018, Poster 667.
I presented the poster on behalf of a the MARS team. The poster presented
the published conference paper, item four (above).
4. Fatemeh Asghariomabad et al. [includes Chiara Lowe]. Intrinsic respiratory
gating for MARS imaging. IEEE Nuclear Science Symposium and Medical
Imaging Conference, Sydney, Australia, November 2018.
Presented by Fatemeh Asghariomabad on behalf of the MARS team.
5. Emily Searle et al. [includes Chiara Lowe]. Distinguishing iron and calcium
using MARS spectral CT, IEEE Nuclear Science Symposium and Medical
Imaging Conference, Sydney, Australia, November 2018.
Presented by Emily Searle on behalf of the MARS team.
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Student support
1. 2017, Merfat Algethami. Merfat was a PhD student from Royal Melbourne In-
stitute of Technology University, Melbourne, Australia. I worked with Merfat
to complete a study determining the benefit of the K-edge value of bismuth and
iodine, using bismuth oxyiodide nanoparticles to enhance contrast in standard
CT imaging and multi-energy (spectral) CT. I designed the scanning protocol
and performed analysis. Refer to Algethami (2018).
2. 2017, Ana Ortega. Ana was a PhD student from the University Carlos III de
Madrid, Spain. My work with Ana involved iodine and silver contrast quan-
tification in chronic pulmonary tuberculosis in excised mouse lung samples. I
contributed towards protocol design for iodine and silver material differenti-
ation, data acquisition and analysis. Refer to Ortega-Gil (2019); Ortega-Gil,
Muñoz-Barrutia, Fernandez-Terron, and Vaquero (2018).
3. 2017, Fatemeh Asghariomabad. Fellow PhD student and MARS team mem-
ber, I helped Fatemeh using my skills in animal handling when performing live
animal scans. I anaesthetised the animals and assisted in using the MARS
scanner, collecting and analysing results. Furthermore, I provided assistance
in LaTeX code writing when Fatemeh required help.
4. 2017, Fanny Solinhac. Fanny was a visiting intern from Bordeaux, France.
My work with Fanny included teaching and supervising use of the MARS-11




1. University of Illinois, Illinois, United States of America. University of Mary-
land, USA. Bone samples and whole rat specimens sent from Illinois were
imaged using the MARS seven-chip research scanner.
xxxiii
Chapter 6 outlines my contributions. The academic outcome of this collabora-
tion was two papers in which I am co-author on.
2. Royal Melbourne Institute of Technology, Melbourne, Australia. Merfat Al-
gethami, a PhD student, was supported by me to complete parts of her studies.
Details above stated in Student support, item one.
3. University of Carlos III, Madrid, Spain. Department of Bioengineering and
Aerospace Engineering. A PhD student worked along side myself for three
months.
Details stated in Student support, item two.
4. Stanford University School of Medicine, Stanford, CA. Collaborating with
Qiong Xu involved assessing spectral information of several contrast agents
Qiong provided us.
I scanned the contrast agents provided by Qiong, analysed the data, and wrote
a report for Qiong.
5. MediLumine Inc. MediLumine provides high quality instruments, reagents,
and accessories to support pre-clinical imaging. Following a successful pilot
study using MediLumine’s contrast agents and the MARS scanner, a partner-
ship between MARS Bioimaging and MediLumine was developed.
I designed the protocol, acquired spectral data of several different contrast
agents using MARS research scanner, and analysed the data to produce suc-
cessful images.
Industrial
1. MARS Bioimaging Ltd. My research through the University of Otago is part
of a large collaborative project with MBI and the Ministry of Business, Inno-
vation and Employment, whose aim is to bring MARS scanners to the clinic.
I have contributed in the following ways: performing image quality assessment,
testing multiple research scanners with different camera sizes; based at the Uni-
versity of Otago and University of Canterbury, providing student support and
teaching, designing phantoms and experiments.
xxxiv
Workshops
1. Thesis writing workshop 15th July 2019, Christchurch, New Zealand.
2. PhD student Workshop 3rd July 2019, Christchurch, New Zealand.
3. MPI and rat training 31st September 2018, Christchurch, New Zealand.
4. MedTech CoRE Annual Conference during HealthTech Week 13th June 2018.
Aotea Centre, Auckland, New Zealand.
5. Exploring options after your degree 13th May 2018, SFB, Atlanta, US.
6. Clinical Awareness Module, 14th-16th November 2017, Christchurch Hospital,
Christchurch, New Zealand.
7. Experimental Methods 9th-13th October 2017, Auckland Bioengineering In-
stitute (ABI), Auckland, New Zealand.
8. Instrumentation and Design 25th-29th September 2017, Auckland Bioengi-
neering Institute (ABI), Auckland, New Zealand.
Awards/financial grants
1. 2019, Student Oral Presentation Prize
I was awarded second place overall prize for student oral presentations at the
Queenstown Research Week conference, Medical Devices and Technology.
2. 2018, Travel Grant
The Canterbury-West Coast Division of the Cancer Society awarded $1000
towards my travels to an international conference; Society for Biomaterials,
Atlanta 2018.
3. 2017, Recipient of a Ph.D scholarship
I was awarded a Doctoral Scholarship for high-achieving domestically-trained





The current chapter begins with my research objectives, followed by a concise intro-
duction to spectral photon-counting computed tomography (CT) and its potential
role in diagnostic molecular imaging. Next, the significance of high-Z contrast and
nanoparticle technology relating to photon-counting CT is discussed. The chapter
concludes with a brief description of the thesis structure.
1.1 Research objectives
MARS spectral scanners are manufactured by MARS Bioimaging Ltd in collabora-
tion with the University of Canterbury and the University of Otago, Christchurch.
A MARS scanner incorporates a photon-counting detector which operates in the
clinical diagnostic X-ray range (30-120 keV) and at high resolution (50-200 µm).
Research investigating spectral photon-counting CT aims to identify, demonstrate,
and refine clinical and preclinical applications. The long term-goal is to put scanners
into clinical practice and be made available for purchase, providing both economic
and health benefits to New Zealand. The aim of the current thesis was to investi-
gate preclinical molecular imaging using MARS scanners. Specifically, the potential
clinical applications of high-Z pharmaceuticals in highlighting disease-related tissue.
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1.2 Photon-counting CT as a novel molecular
imaging tool
Since its clinical introduction in the 1970s, CT has become a well established med-
ical tool, with the number of scans performed rising annually (Commission, Book,
et al., 2012). CT enables the non-invasive visualisation of abnormalities and assists
in diagnostic decision making for a wide range of diseases (Esses et al., 2004). The
increased use of CT can be attributed to its low cost, high spatial resolution, rela-
tive safety, and shorter scan times compared to other scanning modalities, such as
magnetic resonance imaging (MRI) (Hendee & Ritenour, 2003). Clinical diagnostic
imaging technology has evolved and advanced considerably in the past five decades.
Developments have been driven by the “technology push” principle; that is, ongoing
research into new technology drives the development of new products (Hendee &
Ritenour, 2003). Moreover, technologies from areas outside of medicine have had
a notable influence on medical imaging. For example, ultrasound principles were
first developed for submarine detection. Microelectronics for computer aided imag-
ing originated in surveillance and defence applications (Hendee & Ritenour, 2003).
Finally, the development of a novel imaging modality capable of molecular imaging
(spectral photon-counting CT) was influenced by research investigating particle de-
tectors at the European Organisation for Nuclear Research (CERN).
Spectral photon-counting CT aims to provide material characterisation of the
imaged object at high resolution using an energy-resolving detector. Current molec-
ular technologies that are clinically available include functional MRI, single-photon
emission CT (SPECT), and positron emission topography (PET) (Weber, Czernin,
Phelps, & Herschman, 2008). MRI provides excellent soft tissue contrast and func-
tional information without the need for ionising radiation (Tempany & McNeil,
2001). However, compared to CT, MRI has poor spatial resolution, inherently lower
sensitivity for detecting targeted agents, and much higher financial and time cost.
Further, MRI scans cannot be performed on patients with claustrophobia and image
quality is greatly affected by metallic implants and movement artifacts (Hargreaves
et al., 2011; McIsaac, Thordarson, Shafran, Rachman, & Poole, 1998; Smith &
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Nayak, 2010). An advantage of PET imaging compared to CT, is its high intrin-
sic sensitivity which enables measurement of metabolic activity. The disadvantage
of PET and SPECT includes the requirement of an expensive, football field-sized
cyclotron to create radioactive tracers shortly before the scan. PET and SPECT
lack contextual anatomical information, and therefore, often require the addition
of standard CT images which exposes the patient to increased radiation (Jaffer &
Weissleder, 2005).
Other examples of molecular imaging include optical imaging, such as biolu-
minescence and near-infrared fluorescence (NIRF). Fluorescence is sensitive and
has adequate spatial resolution for use in in-vivo imaging and clinical applications
such as retinal angiography, cardiovascular surgery, and gastrointestinal endoscopy
(Jaffer & Weissleder, 2004). However, clinical applications for optical imaging are
greatly limited by poor penetration depth (Mezzanotte, vant Root, Karatas, Goun,
& Löwik, 2017). Thus, as spectral photon-counting CT develops and achieves its
potential, it promises to complement current imaging modalities by offering material
characterisation, reduced metal artifacts (Butler et al., 2019; McCollough, Leng, Yu,
& Fletcher, 2015; R Amma, thesis submitted Janurary 2020), lower radiation dose
to the patient (Symons et al., 2016, 2017), and higher spatial resolution (Butler et
al., 2019). These are all important aspects that will enable quick, accurate diagnosis
by radiologists and ultimately lead to improved patient outcomes.
1.3 Integration of contrast agents for molecular
imaging
1.3.1 High-Z CT contrast
Not long after the discovery of X-rays, contrast materials were used to address the
limitations of soft tissue differentiation. That is, without contrast material, it is
difficult to distinguish one type of soft tissue from another (Taguchi & Iwanczyk,
2013). Contrast materials are elements that possess a high atomic number (high-Z)
which absorb X-rays and enhance the X-ray signal (appear bright). In comparison,
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soft tissues are a low density material which absorb X-rays to a lesser extent (appear
dark). Thus, when contrast materials are used, the resulting image provides a clearer
picture of the different tissues or structures scanned. Lower X-ray photon energies
(<50 kilovoltage peak; kVp) provide more signal (greater contrast), since photo-
electric events are the predominant interaction (Carlton & Adler, 2012). Therefore,
high-Z material plays an important role in improving the contrast in higher energy
scans (Webb, Stacul, Thomsen, Morcos, et al., 2003; Zukiwski et al., 1990).
A study in 1896 by Haschek and Lindenthal used bismuth, lead, and barium salts
to develop the first angiogram of a severed hand (Pavcnik, 2014; Quader, Sawmiller,
& Sumpio, 2000). The first contrast materials developed were not safe for use in live
humans. Continuous research into structural modifications of contrast materials has
led to vast improvements in stability, toxicity, osmolarity, and specificity (Quader
et al., 2000; Roh & Laroia, 2015). Currently, water-soluble iodine-based contrast is
the most widely used in X-ray CT imaging (N. Lee, Choi, & Hyeon, 2013; Lusic &
Grinstaff, 2012). Several iodinated contrasts are clinically available, including Omni-
paque (OmnipaqueTM , GE Healthcare), Iopromide (UltravisTM , Bayer Healthcare),
Ioxaglate (HexabrixTM , Mallinckrodt Imaging), Iobitridol (XenetixTM , Guerbet),
and Iomeprol (Imcron, Bracco) (Mahan & Doiron, 2018).
1.3.2 Nanoparticle-based contrast
An important factor to consider regarding contrast material is the osmolarity, which
refers to the number of particles in a solution. Toxicity of a contrast decreases as
osmolarity nears that of serum (of Radiology et al., 2015). A higher osmolarity
is associated with a greater incidence of adverse-effects (Lusic & Grinstaff, 2012;
Thomsen, Webb, et al., 2006). During the course of a coronary arteriography, up to
150 mL, totalling 48 g of iodinated contrast may be administered (Lusic & Grinstaff,
2012). The requirement of high concentrations of contrast for CT is a disadvantage
when compared to other imaging modalities, such as MRI and nuclear imaging,
which are in the mmol and µmol range, respectively. High osmolarity, concentra-
tion, and viscosity associated with iodine-based contrast can lead to poor patient
tolerance and serious adverse effects (Lusic & Grinstaff, 2012). In addition, iodine-
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based contrast is limited by short blood pool circulation time and poor contrast in
larger patients (N. Lee et al., 2013; Mattrey & Aguirre, 2003; Szucs-Farkas, Verdun,
von Allmen, Mini, & Vock, 2008). Thus, a constant area of research and devel-
opment is establishing CT contrast that possesses maximum imaging capabilities,
reduced toxicity (low osmolarity), and minimal dose.
Manipulation of structures on the nanometre scale has led to an exponential
increase in research and development of nanoparticles for use in diagnostic imaging
of cardiovascular disease (Bawarski, Chidlowsky, Bharali, & Mousa, 2008; Galvin et
al., 2012; Godin et al., 2010), cancer (Galvin et al., 2012; Seigneuric et al., 2010),
infectious disease (Taylor & Webster, 2011), and theranostic applications (Sajja et
al., 2009). Theranostics was a term coined to describe multifunctional nanoparti-
cles capable of therapeutic and diagnostic functions (discussed further in Section
1.3.2.1). An advantage of nanoparticle-based contrast is lower osmolarity, as more
atoms per particle are delivered compared to standard bulk contrast. For exam-
ple, 250 atoms of gold (in nanoparticle form) are delivered compared to 3-6 atoms
of standard iodine (Anselmo & Mitragotri, 2016; He, Ai, & Lu, 2015; Silvestri et
al., 2016). Another advantage of nanoparticle contrast is improved solubility. This
property may provide the ability to transform poorly soluble bulk drugs into soluble
solutions and reduce the need for toxic organic solvents (Bharali & Mousa, 2010;
Sharma, Madhunapantula, & Robertson, 2012).
Nanotoxicology is an important aspect of nanotechnology that aims to find the
relationship between the physical and chemical characteristics of the nanoparticle
and the induction of toxic cellular responses (Lamberti, Zappavigna, Sannolo, Porto,
& Caraglia, 2014). The current thesis investigated gold and hafnia in nanoparticle
form. Nanotoxicity is considered outside the scope of focus for this PhD. However,
it is worth noting that there is a substantial body of literature regarding gold nan-
otoxicity (Chen, Hung, Liau, & Huang, 2009; Jia, Ma, Wei, & Qian, 2017; Umair et
al., 2016). Further, early investigations into hafnia nanotoxicity have been carried
out within the MARS program (Ostadhossein et al., 2020).
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1.3. Integration of contrast agents for molecular imaging
1.3.2.1 Functionalisation of nanoparticles
Nanotechnology is helping revolutionise drug delivery for the treatment of cancer
(Daraee et al., 2016; Dykman & Khlebtsov, 2016; Pissuwan, Niidome, & Cortie,
2011). Many properties of conventional pharmacological drugs can be improved
using nano-based drugs (Caraglia et al., 2012). A key aspect that gives nanopar-
ticles the ability to function as a drug carrier is their large surface area relative to
size, which enhances reactivity, bioavailability, and surface chemistry (Bawa, 2011;
Hainfeld, Slatkin, Focella, & Smilowitz, 2006; Poirot-Mazeres, 2011; Sapsford et al.,
2013). Versatile surface chemistry enables conjugation of electrostatic biomolecules
(functionalisation) for carrying drugs and targeting purposes (Bawa, 2011; Godin
et al., 2010). Nanoparticle size, size distribution, and surface molecules are the
characteristics that determine the in-vivo distribution, drug release, toxicity, and
targeting ability (Lamberti et al., 2014; Roger, Lagarce, Garcion, & Benoit, 2010).
Typically, nanoparticles are recognised by the body’s immune defences and safely
removed from the circulatory system by phagocytic cells. This is known as the retic-
uloendothelial system (Roger et al., 2010).
Due to their small size (1-100 nm diameter), nanoparticle-based contrast benefits
from increased circulation time and permeability. This leads to the drug concentra-
tion remaining high and effective within the body for an extended period of time
(Cai, Gao, Hong, & Sun, 2008; Galvin et al., 2012; Seigneuric et al., 2010). Min-
imising phagocytosis and increasing circulation time is often achieved by function-
alisation with biodegradable surface molecules, such as polyethylene glycol (PEG)
(Lamberti et al., 2014). Nanoparticle functionalisation can further improve the ef-
fectiveness of a drug by providing targeted delivery, prolonged drug effects, and
feedback regarding drug efficacy (Godin et al., 2010). For a nanoparticle complex
to be affective as a drug delivery vehicle, criteria described by Figure 1.1 must be
fulfilled.
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Figure 1.1: (a) The nanoparticle complex must be stable in solution for systemic delivery.
(b) The nanoparticle releases the drug once at the site of interest. (c) The nanoparticle
complex must only deliver the drug to the tumour cells, that is, selective or targeted
delivery. (d) Once the drug has been delivered, clearance of the nanoparticle by the body
can occur (Thakor & Gambhir, 2013).
The first Food and Drug Administration (FDA) approved anti-cancer (ovarian
cancer) nanomedicine was the liposomal-based nanoparticle doxorubicin hydrochlo-
ride injection (Doxil, Ortho Biotech). Research found doxorubicin hydrochloride
provided a number of benefits, including a long circulation time compared to cur-
rent iodinated contrast (Allen & Cullis, 2013), stable drug loading and releasing to
targeted cells (Barenolz & Haran, 1993; Horowitz, Barenholz, & Gabizon, 1992), and
significant enhancement of drug delivery to tumours (4-16 fold increase) compared to
its non-functionalised drug counterpart (Gabizon et al., 1994). Another liposomal-
based nanoparticle, daunorubicin citrate, was also FDA approved for use in advanced
AIDS-related Kaposi’s sarcoma (Galvin et al., 2012; Sajja et al., 2009). Finally,
there are several forms of nanoparticles available clinically and in research, includ-
ing liposomes, polymeric micelles, metallic, dendrimers, and solid lipid nanoparticles
(Seigneuric et al., 2010).
1.3.2.2 Nanoparticles and photon-counting CT
There are several forms of nanoparticles available clinically and in research. How-
ever, metallic or high-Z nanoparticles are ideal for spectral photon-counting CT
due to their attenuating properties (Seigneuric et al., 2010). High-Z functionalised
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nanoparticles could actualise the full potential of spectral photon-counting CT as
a non-invasive molecular imaging tool. High-Z nanoparticles can be designed and
produced in various shapes, sizes, and porosity with great reproducibility (Thakor
& Gambhir, 2013). In addition, high-Z nanoparticles can be easily conjugated to
ligands and/or therapeutic drugs for targeted tumour imaging and/or therapy. Com-
pared to liposomes and solid lipid nanoparticles, high-Z nanoparticles are relatively
stable for a large range of temperature and pH levels, (Thakor & Gambhir, 2013).
Spectral photon-counting CT integrated with nanoparticle technology may ad-
dress limitations faced by current standard iodinated contrast (such as high osmolar-
ity) and molecular imaging modalities (Kim et al., 2018). There is some uncertainty
and concern regarding the slow dissolution of high-Z nanoparticles and their safe
elimination from the body. Despite these concerns, several high-Z nanoparticles have
been successfully utilised for contrast-enhanced CT imaging, including silver (Cui
et al., 2017), bismuth (Cheng & Zhang, 2018), gold (Boisselier & Astruc, 2009), and
hafnia (McGinnity et al., 2016). In summary, spectral photon-counting CT promises
simultaneous quantification of multiple materials, whilst nanoparticle-based contrast
provides unique structural properties that bulk materials do not possess.
1.4 Thesis structure
Chapter 2 begins by describing the principles of conventional CT, Dual-energy CT,
and photon-counting CT detector technology. Material decomposition (MD) and
the methodology used throughout the current thesis will be presented. Finally, pre-
clinical challenges currently faced by photon-counting CT technology are discussed.
Refer to the substantial body of literature available for knowledge on the basics of X-
ray CT physics (Bushong, 2013; Danad, Fayad, Willemink, & Min, 2015; Haidekker,
2013; Pessis et al., 2013; Podgorsak et al., 2005).
Chapter 3 discusses important concepts of image quality used by researchers and
clinicians to assess preclinical and clinical imaging modalities. These concepts are
related back to the photon-counting system used in the current thesis.
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Chapters 4 to 6 present my experimental research. Chapter 4 begins with imag-
ing of a non-specific, standard CT contrast material (iodine) in infectious disease.
A second non-specific contrast (silver) is used to demonstrate multiple high-Z mate-
rial differentiation. Chapter 5 presents imaging of gold nanoparticles functionalised
with monoclonal antibodies targeted to two different cancer cell types: breast cancer
(SKBR3) and lymphoma (Raji). Finally, Chapter 6 is divided into two experiments:
(1) functionalised hafnia nanoparticles (HfNPs) for bone micro-damage imaging;
and (2) HfNPs packed inside probiotics for gastrointestinal imaging. Each of my
research chapters include an introduction, materials and methods, results, discus-
sion, and summary section. The introduction provides a comprehensive background
as to why the particular application was selected and suitable for MARS imaging.
The discussion and summary conclude the chapter by summarising the results and
providing suggestions for future work to further advance the current research.
Chapter 7 concludes the present thesis and provides a discussion on the impli-






The current chapter provides prerequisite information for understanding the main
body of this thesis. Firstly, the development of X-ray CT detection is discussed, set-
ting the stage for my research regarding molecular imaging using photon-counting
CT detector technology. Debate over the key term “spectral” when used in the
context of CT imaging is clarified by comparing conventional CT, dual-energy
CT (sometimes referred to as spectral or multi-energy CT), and spectral photon-
counting CT. Secondly, basis MD, employed throughout the current thesis, and MD
assessment/analysis will be presented. A brief description of the current limitations
faced by photon-counting CT technology concludes the present chapter.
2.1 Development of CT imaging
Since discovered in 1895 by Wilhelm C. Rontgen, X-rays have played a critical role
in medical imaging. X-rays (photons) are the product of electrons colliding with an
anode (Podgorsak et al., 2005). A tungsten anode is used in medical applications to
produce a polychromatic X-ray beam. Once passed through the object, photons are
captured by a detector and a projection image is generated (Michette & Buckley,
n.d.; Rajendran, 2016). Projection images are captured from multiple angles around
the object to provide 3D information. The technique in which photons are detected
and CT image generated has significantly improved since single-use photographic
film (Evans, Workman, & Payne, 2001; Leblans, Vandenbroucke, & Willems, 2011;
Sonoda, Takano, Miyahara, & Kato, 1983).
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2.1. Development of CT imaging
The motivation to move away from film and toward digital radiography includes
improved image quality, lower radiation dose, shorter exposure (and thus more effi-
cient patient throughput), and the capability of storing images electronically (Kotter
& Langer, 2002). The same motivations continue to fuel the development of novel de-
tector technology. Photon-counting CT detectors have the potential to significantly
aid and improve clinical diagnostic imaging. Section 2.1.1 compares conventional
CT (energy-integrating) to photon-counting CT (energy-resolving). The advantages
and challenges of photon-counting CT technology is discussed. These concepts are
related back to the photon-counting detector used in this thesis; the Medipix3RX.
2.1.1 Energy-integrating vs. photon-counting detectors
Photons captured by the detector are processed by one of two methods: indirect
and direct conversion (see fig. 2.1). Two main detectors utilised in conventional
CT systems are charge-coupled devices (CCDs) and flat-panel detectors (FPDs).
CCDs and FPDs convert X-rays into visible light using a scintillator. A scintillating
material fluoresces when struck by a high-energy photon or charged particle (Yaffe
& Rowlands, 1997). The scintillator is coupled with a photodiode (semiconduct-
ing material) which generates an electrical signal proportional to the total energy
deposited during one measurement interval (Kotter & Langer, 2002; Willemink,
Persson, Pourmorteza, Pelc, & Fleischmann, 2018). Thus, CCDs and FPDs are
energy-integrating. That is, the intensity of the transmitted beam is captured, not
the X-ray beam energy spectrum. This means energy-integrating systems fail to
capture spectral information (Taguchi & Iwanczyk, 2013). Moreover, the output
signal of an energy-integrating system is biased towards the signal generated from
high energy photons, since high energy photons are less likely to be attenuated.
Consequently, contrast-to-noise ratio (CNR) is not optimal, as high energy photons




Figure 2.1: Schematic showing indirect (a) and direct (b) X-ray conversion (Willemink et
al., 2018).
The interactions that occur between the beam and object are strongly dependent
on photon energy. Dual-energy CT (DECT) was first described in 1973 and later in-
troduced clinically in 2006 (Itounsfield, 1973; Taguchi & Iwanczyk, 2013). DECT is
an energy-integrating CT system that offers spectral information and material char-
acterisation by measuring two different energy spectra (T. R. Johnson et al., 2007).
There are three main techniques employed by DECT to achieve material charac-
terisation: (1) dual X-ray source, (2) a single source that rapidly switches between
two kVps during exposure, (3) and dual sensor layers (see fig. 2.2) (T. Johnson,
Fink, Schönberg, & Reiser, 2011; Wu et al., 2009). DECT imaging is often referred
to as spectral or multi-energy CT imaging. However, optimal material characteri-
sation is not possible due to cross-talk between the high and low acquisition steps
(overlapping spectra) (Alvarez & Macovski, 1976a). Furthermore, DECT imaging
is associated with an increased cost of radiation exposure to the patient due to
utilisation of two energy spectra.
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Figure 2.2: Illustration of data acquisition methods for DECT. 1: dual source, 2: single
source that rapidly switches between two kVps during the scan, 3: single tube with dual
layer detection, 4: single source with split filter, 5: single source with sequential scans
(Goo & Goo, 2017).
In contrast to FPDs and CCDs, photon-counting CT detectors consist of a single
thick semiconductor sensor layer on which a large voltage is applied (Willemink et al.,
2018). The Medipix3RX is the most recent photon-counting CT detector utilised
by MARS scanners to simultaneously measure 5-8 energies in a single exposure
(Ballabriga, Campbell, Heijnel, Llopart, & Tlustos, 2006; Iniewski, 2016; Llopart,
Campbell, Dinapoli, San Segundo, & Pernigotti, 2002; Raja et al., 2014). It operates
at high resolution (50-200 µm) and uses the conventional CT broad X-ray spectrum
(30-120 keV). A single exposure reduces the radiation cost to the patient (Anderson
& Butler, 2014; Walsh et al., 2013; Watt et al., 2003). Four energy bins operate
in charge summing mode (CSM). CSM works by summing the charge over four
neighbouring pixels and allocating the total charge to the pixel with the highest
charge. This technique minimise the effect of charge sharing (Hamann et al., 2014).
Figure 2.3 illustrates the simultaneous measurement of four energies.
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Figure 2.3: A photon-counting CT detector works by dividing the X-ray spectrum (here
produced by a tungsten anode) into a number of energy bins. Bremsstrahlung radiation
is produced by electrons high in kinetic energy interacting with the nucleus of a target
atom (deflection in the Coulombic field). Characteristic radiation is produced when an
inner-shell electron is ejected from the atom. An outer-shell electron fills the vacant hole
left by the ejected electron. As the electron drops to the inner-shell, excess energy is
radiated as a photon (Bushong, 2013; Haidekker, 2013; Willemink et al., 2018).
The Medipix3RX directly converts the energy deposited by a photon into an
electrical pulse using a cadmium zinc telluride (CZT) sensor layer. The height of
electrical pulses are compared to user defined thresholds and subsequently binned,
as shown in Figure 2.4. Removing intermediate steps (direct conversion) provides
superior resolution and high photon detection efficiency in the human diagnostic en-
ergy range (Iniewski, 2014; Sellin, 2003). Furthermore, differences in photon counts
between two subsequent bins can be calculated with almost no overlapping spectra.
No overlapping spectra increases energy resolution and sensitivity (Fornaro et al.,
2011; Moghiseh et al., 2016). Moreover, measurement of individual photon energy
improves CNR 10-20% by (1) eliminating electronic noise and (2) all X-ray ener-
gies contribute equally to the signal. That is, there is no bias towards the signal
generated from high energy photons (Shikhaliev, 2009; Suetens, 2017; Willemink et
al., 2018). To summarise, Figure 2.5 illustrates the differences in photon detection
between conventional CT, DECT, and the Medipix3RX (photon-counting CT).
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Figure 2.4: Schematic illustrating the principle of a photon-counting detector. Each pho-
ton deposits energy which generates an electrical pulse proportional to the energy de-
posited. The area under the signal curve is associated with energy integrating detectors,
which provides less information compared to photon-counting detectors (Willemink et al.,
2018).
Figure 2.5: Schematic of conventional CT, DECT , and MARS photon-counting CT. Con-
ventional CT provides anatomical imaging only, DECT offers limited material discrimina-
tion. In contrast, MARS offers multiple material discrimination and quantification.
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2.1.2 Spatial resolution
Each detector element in a standard CT system is kept separate to avoid cross-
talk generated in the scintillator (Willemink et al., 2018). This separation prevents
smaller detector pixels being manufactured (1 x 1 mm2), thus limiting spatial res-
olution (Willemink et al., 2018). Photon-counting CT detectors do not require a
scintillator, therefore, can be made with smaller pixels (Medipix3RX pixel size: 110
µm x 110 µm). Smaller pixels provide greater spatial resolution which enables visu-
alisation of fine structures (Baek, Pineda, & Pelc, 2013). Superior spatial resolution
has proved useful for breast cancer, lung imaging, coronary artery disease, and com-
plex fractures of small bones, such as wrist bones by providing greater specificity
(Leng, Gutjahr, et al., 2017; Rossler et al., 2017; Shikhaliev, 2015; Zhou et al., 2017).
2.2 Material decomposition
MD through the conversion of dual-energy measurements into Compton and pho-
toelectric cross-section components was initially demonstrated by Alvarez and Ma-
covski (1976b), and later by Brody, Butt, Hall, and Macovski (1981). Figure 2.6
graphically illustrates how human tissue can be represented by a coordinate on two-
dimensional axes, with water and calcium on each axes. Although human tissue isn’t
entirely comprised of calcium or water, it has an equivalent X-ray attenuation to a
combination of these materials at all energies (Willemink et al., 2018). Simultane-
ous measurement of attenuation in a small number of energy bins provides sufficient
data (basis functions) for determining the energy dependence of the attenuation





Figure 2.6: (a) Material within the human body can be represented by a 2D diagram
with concentrations of calcium and water on the axes. (b) A high-Z contrast material,
such as iodine, adds a third dimension to the diagram. Thus, the contrast material can
be separated from body tissues and measured (Willemink et al., 2018).
When performing MD on a number of energy bins, a set of material image
datasets can be generated (see fig. 2.7). Each material dataset provides quantita-
tive (concentration or density) information for one material. In principle, one or
two energy bins (conventional CT and DECT, respectively) would be suffice for the
quantitative measurement of water and calcium. Three energy bins would be suffi-
cient if a high-Z material was added (Roessl & Proksa, 2007). However, a greater
number of energy bins is associated with reduced image noise in the material datasets
due to improving the precision of measurement of an individual photon (Faby et al.,
2015; Shikhaliev, 2008). In addition, simultaneous quantification of multiple high-
Z materials and human tissues is made possible with a greater number of energy
bins (Moghiseh et al., 2016; Raja et al., 2018). MD obtained from photon-counting
CT data eliminates the trade-off between beam hardening and CNR (a limitation of
energy-weighted images) and quantifies iodine contrast more accurately than DECT
(Leng, Zhou, et al., 2017; Willemink et al., 2018; Yeh et al., 2017).
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Figure 2.7: Photon-counting CT detectors enable provides energy-specific data. Basis
MD is performed using the energy images to produce material image datasets. The ma-
terial datasets can be analysed separately, or combined to create a final spectral image
(Willemink et al., 2018).
MD methods have adapted since dual-energy measurements to incorporate the
measurement of multiple energies. The least squares method has been shown to per-
form basis MD for multiple materials from data measured in five energy bins (Le &
Molloi, 2011; X. Wang, Xu, & Frey, 2007). Basis MD works by the observation that
the linear attenuation coefficient of a specific material can be closely approximated
using a linear combination of a small number of basis functions. The fundamen-
tal principle that different materials possess different mass attenuation coefficients
(µ/ρ) across the human diagnostic energy range is exploited. The current thesis em-
ploys an in-house MD algorithm (MARS-MD) which uses a constrained linear least
squares method. MARS-MD is applied in the image domain using mass attenuation
information obtained from a calibration phantom (Bateman, 2015; Bateman et al.,
2018). Sections 2.2.1 to 2.2.3 present methodology for energy threshold selection,
calibration phantom information analysis, and MARS MD image evaluation.
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2.2.1 Energy threshold selection
An increased number of bins is accompanied by the need to evaluate energy threshold
positions. Related to MARS scanners, an arbitrary counter is set by the manufac-
turer above the noise floor. Users have a choice to employ or remove the arbitrary
energy bin. Determining subsequent thresholds of the CSM bins is crucial for high
spatial and energy resolution. For example, a narrower bin will detect fewer pho-
tons which can result in decreased signal-to-noise ratio (SNR). Several studies have
examined the selection of optimal energy thresholds. For example, a study by Beld-
joudi, Rebuffel, Verger, Kaftandjian, and Rinkel (2012) found an increase in material
identification success of homogeneous plastic with an increase in bin number, until
the performance level of the photon-counting detector was reached. Analytical ap-
proaches to energy threshold selection have also been investigated (Roessl & Proksa,
2006; A. S. Wang & Pelc, 2010). More recent studies by Panta, Bell, et al. (2018)
and Moghiseh (2018) evaluated the imaging performance of different energy thresh-
olds for the discrimination of five and six materials, respectively. The thresholds
were optimised based on the atoms K-edge and energy dependent X-ray attenuation
features of the materials of interest (see fig. 2.8).
Figure 2.8: X-ray absorption or attenuation as a function of energy (keV) for water, bone,
and contrast material: iodine. The K-edge of an element/atom is the binding energy of
an innermost electron (K-shell electron). A step-change or enhancement in attenuation at
a particular energy occurs due the K-edge. A K-edge within the diagnostic energy range
(for example iodine has a K-edge of 33.2 keV) enables that high-Z material to be identified
uniquely using an energy resolving detector.
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In the present thesis, four charge summing mode (CSM) energy bins were utilised
to provide a balance between obtaining sufficient spectral information and having a
manageable amount of data. Determining threshold placement involved exploiting
the K-edge effect (Cormode et al., 2010; Müllner, Schlattl, Hoeschen, & Dietrich,
2015). The K-edge causes an enhancement in mass attenuation (cm2/g) and is ob-
served at the minimum energy required (see fig. 2.8). For example, the K-edge of
hafnium is 65.4 keV, thus, thresholds placed either side of 65.4 keV will result in
a peak in mass attenuation between the thresholds. Maximising the difference in
basis functions will aid in material characterisation.
Theoretical mass attenuation coefficient data for high-Z materials were obtained
from the National Institute of Standards and Technology (NIST XCOM; https://phy
sics.nist.gov/). The materials investigated in the current thesis included iodine and
silver in Chapter 4, gold in Chapter 5, and hafnium oxide (hafnia) in Chapter 6.
NIST data enabled the theoretical spectral response to be evaluate by selection of
potential energy thresholds, as shown in Figure 2.9. The average attenuation of
the photons for a set of energy bins (30-45, 45-65, 65-80, and 80-120 keV) for each
material is displayed in Figure 2.9b. Measured HU is displayed on the y-axis.
(a) (b)
Figure 2.9: (a) Mass attenuation coefficients for calcium and two high-Z materials for
different photon energies. Vertical dotted lines indicate user-defined energy thresholds
which create four CSM energy bins. (b) Resulting spectral response: enhancement in
attenuation in the third energy bin (65-80 keV) for hafnium is due to the K-edge (65.4
keV). Area under the curve is evaluated to spectrally separate calcium and iodine.
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2.2.2 Calibration phantom analysis
A semi-automatic in-house MATLAB program written by a MARS team member
(Moghiseh, 2018) was employed for calibration phantom analysis. Figure 2.10 shows
a schematic illustrating the measurement of linear attenuation of iodine-based cali-
bration vials (orange) and lipid (yellow) from an axial slice. The spectral response
is evaluated by plotting HU (converted from the linear attenuation values) against
energy bin (7-26, 26-34, 34-45, 45-60 keV).
Figure 2.10: Schematic of a calibration phantom containing iodine (2.25, 4.5, 9, and 18
mg/mL), lipid, and water. An in-house program enables semi-automatic evaluation of the
spectral response by measuring HU (y-axis) within each vial for each energy bin (x-axis).
The linearity of the spectral response (linearity response) describes the rela-
tionship between HU and material concentration (Moghiseh et al., 2016; Zainon,
Ronaldson, Butler, & Butler, 2015). Poor linearity of attenuation can result in
reduced accuracy of material quantification. Linearity is established by plotting
measured attenuation values (HU) against concentration of a given material for
each energy bin, as shown in Figure 2.11. The least squares linear regression, R2,
represents the accuracy of the linear relationship between HU and material concen-
tration. If R2 is close to 1, and the solution is stable (no precipitation), linearity is
considered established and MD measurements can be confidently relied on to mea-
sure unknown concentrations of the basis material.
Selection of material concentration for use in the calibration phantom can have a
significant effect on the success of material identification and quantification (Moghiseh,
2018). Thus, it is important to note Chapter 3 presents the analysis of a multi-
material phantom for QA purposes that contained fewer than three concentrations
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of a number of materials. However, the purpose of Chapter 3 was to quickly identify
the difference between scans using the same protocol and assess the image quality.
All experimental chapters carefully considered the calibration phantom materials
and concentrations (Curtis & Roeder, 2017).
Figure 2.11: An in-house program enables semi-automatic evaluation of the linearity re-
sponse by plotting measured attenuation (y-axis) against concentration. Each linear line
represents one energy bin.
2.2.3 Material decomposition analysis
MARS-MD was evaluated for each imaging application in the current thesis. Quanti-
tative analysis looked at the percentage identification success of the calibration phan-
tom vials using a semi-automatic in-house program written in MATLAB (Moghiseh,
2018). A region of interest within one slice of the water material dataset is first se-
lected, for example the 2 mg/mL gold vial, as shown in Figure 2.12a. The same
region of interest is measured within the gold, water, and lipid material datasets.
Ideally, gold is only measured in the gold material dataset. However, the MD step is
not perfect, and misidentification can occur. Figure 2.12b presents material identifi-
cation success for three gold vials: 2, 4, and 8 mg/mL. At 8 mg/mL, gold is correctly
identified in approximately 95% of voxels. This decreases to approximately 80% for
2 mg/mL of gold. Multiple slices (8-10) were used to calculate material identifica-
tion success. Established by Moghiseh (2018), ≥80% material identification success
is considered acceptable.
Photon-counting CT imaging promises improved material characterisation by
providing more accurate quantification (Willemink et al., 2018). Material quantifi-
cation was assessed by measuring the mean concentration of the calibration phantom
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vials in the MARS-MD images and comparing this to the actual concentration. The
measured concentration from MD images can be plotted against the known concen-
tration to reveal a linear correlation or lack thereof.
(a)
(b)
Figure 2.12: (a) Region of interest selected in one slice to measure gold voxels. (b) Identi-
fication success for 2, 4, and 8 mg/mL gold. The lowest Au concentration shows misiden-
tification; lipid and water appear in the Au vial. The concentration that presents the
highest amount of misidentification can be used to determine the minimum concentration
of that material visualised in the sample, using MARS Vision.
2.3 Limitations
There are still a number of technical challenges that must be overcome before photon-
counting detectors are clinically available and widely used. The present section
describes pulse pile-up, charge sharing, cross-talk, and chip gap: factors respon-
sible for non-ideal photon-counting detectors and for the deterioration of image
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quality. These factors degrade spatial resolution (Shikhaliev, Fritz, & Chapman,
2009), contrast-to-noise ratio (Michel et al., 2006; J. Xu et al., 2014), and energy
resolution. Reliability of the spectral information is reduced, resulting in noise or
misidentification in the tissue-specific images (Roessl et al., 2011; Shikhaliev et al.,
2009). Moreover, MD algorithms are presently under development to achieve more
accurate material information.
Pulse pile-up: Up to several hundred million photons interact with the detector
per mm2, per second. Thus, the sensor material and readout electronics must be
able to count pulses quickly enough (Willemink et al., 2018). Sufficiently fast and
stable detectors which function at clinical X-ray energy ranges have only become
available recently (Kappler et al., 2014). Pulse pile-up occurs if photons arrive too
fast and the electrical pulses superimpose on each other. Two lower energy pho-
tons arriving almost simultaneously are registered as a single higher energy photon
(Anjomrouz et al., 2018; Cammin et al., 2014). The phenomenon of pulse pile-up is
still an active area of research for photon-counting detectors (Ali Atharifard, 2018;
Panta, Butler, et al., 2018).
Charge sharing: Due to small pixel size, the energy of a single photon can
be shared between neighbouring pixels. Multiple events of lesser energy can be
recorded, rather than a single high energy event, which degrades spatial and spec-
tral resolution (Gimenez et al., 2011; Jakubek, 2009; C. Xu, Danielsson, & Bornefalk,
2011). MARS scanners operate four energy bins in CSM (CSM is described in Sec-
tion 2.2.1) to minimise the effect of charge sharing (Hamann et al., 2014).
Cross-talk: Cross-talk occurs largely due to Compton scatter within the sen-
sor material. A single photon can be counted in more than one detector element
(Bornefalk & Danielsson, 2010). Medipix3RX addresses the issue of cross-talk by
using CZT sensor material, for which the probability of Compton scatter is low
(Willemink et al., 2018).
25
2.4. Summary
Chip gap: Manufacturing of sensor layer crystals have, thus far, posed a prac-
tical challenge which limits the size of detector chips. To create a larger detector
array, detector chips must be placed adjacent to each other which introduces a gap
(considered as dead pixels) between the chips. A potential consequence of the de-
tector gap are ring artifacts. For MARS imaging, the chip gap is addressed and ring
artifact minimised by use of a pixel mask.
2.4 Summary
• CT technology has undergone numerous advances over the last four decades.
Energy-resolving detectors, which provide direct conversion of X-rays, are gain-
ing traction as the next big step in CT evolution.
• DECT is suboptimal in its ability to provide material characterisation due to
overlapping spectra. DECT is associated with increased radiation cost to the
patient.
• Photon-counting detectors are energy resolving, that is, they count individual
photons and measure each photon’s energy.
• Energy dependence of the linear attenuation coefficient of materials can be
described as a combination of the photoelectric effect and Compton scattering
cross-sections.
• A constrained linear least squares method is employed for an in-house MD
program (MARS-MD) in the current thesis.
• Energy threshold selection influences the outcome of basis functions and thus
the result of material differentiation. Therefore, energy threshold selection is
a crucial step.
• The calibration phantom step is important for accurate material information.
• The MD employed in the current thesis was the MD algorithm available at the
time of performing experiments. MD is under constant development, which






The current chapter discusses the importance of quality assurance (QA) with re-
gards to the MARS scanner. Regular QA testing evaluates image quality over time,
thus image quality stability, which is important for clinical and preclinical study
repeatability. Concepts presented in this chapter have contributed to publications
(Marfo, E and Anderson, N. G and Butler, A. P and Schleich, N and Carbonez,
P and Damet, J and Lowe, C and Healy, J and Chernoglazov, A.I and Moghiseh,
M and Raja, A. Y., 2020; Raja et al., 2018). MARS research scanner (V5.1 (2016)
S/N:11), held at the University of Otago, Christchurch campus, was upgraded from
a single-chip Medipix3RX detector (camera) to a three-chip camera. It is important
to note that the aim of the current chapter was not to perform a comprehensive data
acquisition related image quality assessment; rather, the general goal was to observe,
following hardware changes, how image quality could be maintained. Maintaining
image quality is important so that the results obtained from scans are reliable, re-
producible, and consistent. Thus, following QA I performed, the scanner was able
to be leased for usage by other researchers and for my studies (Chapters 4, 5, 6).
Image quality performance of the single-chip camera was used as a benchmark to




Image quality is a standard term used in the assessment of almost all preclinical
and clinical imaging modalities. The detrimental impact that less-than-ideal image
quality can have on image interpretation, diagnostic outcome, and ultimately pa-
tient care, is significant (Rubin, 2011). Demand for relevant and accurate image
quality characterisation has naturally expanded with the development of CT tech-
nology. In standard radiology and mammography, the DQE (Detective Quantum
Efficiency as described in IEC 62220-1/2) is employed to assess the efficiency of
X-ray conversion into image information. However, DQE is not feasible for CT due
to reasons associated with geometry and complex data processing (Verdun et al.,
2015). Furthermore, many standard metrics, such as receiver operating characteris-
tic and visual grading analysis, cannot be used directly for iterative reconstruction
(IR) techniques (MARS employs an IR technique) (Verdun et al., 2015). For photon-
counting CT technology where every pixel is essentially a detector, the complexity of
image quality assessment increases. Applying relevant metrics for specific protocols
enables appropriate comparison and optimisation of the photon-counting imaging
system in question.
Traditional objective indicators used to characterise CT image quality include:
signal-to-noise ratio (SNR), signal difference-to-noise ratio (SDNR), contrast-to-
noise ratio (CNR), modulation transfer function (MTF), and spatial resolution
(Verdun et al., 2015). The current chapter uses two standard indicators, spatial
resolution and SNR, and a third non-standard indicator. The third indicator is re-
ferred to as material identification, which aims to characterise the performance of
tissue-specific images (Raja et al., 2018).
3.1.1 Geometry of MARS scanner
MARS research scanners have a total of 12 motors that control the sample transla-
tion, gantry rotation, X-ray source and detector/camera magnification, and camera
offset (see fig. 3.1). The addition of camera offset motors enable larger objects to be
scanned with current smaller cameras by increasing the virtual camera size. Over
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time and following hardware upgrades, sources of image quality degradation include
inaccurate camera offset, magnification, and change in field of view (FOV) (Raja,
2013; Uddin, 2019). MARS point-of-care arm scanners, which have a significant
reduction in motors and increased camera size, are currently being built and tested.
The reduced number of motors will enhance image quality stability.
The key parameters most frequently disturbed by camera hardware changes,
and the major focus of the current chapter, are the camera offset parameters (axial
and tangential) and FOV. Therefore, optimisation of the camera offset parameters
was performed following installation of the three-chip camera. Tangential and axial
offset values relate to the offset of the perpendicular ray from the source to the
camera. They provide the “actual” camera and source positions which differ from
the physical centre of the camera. Moreover, the effect of FOV on image quality
under ideal conditions, that is, the camera offset parameters are correct and there are
no geometric errors, was investigated. A larger camera enables larger specimens to
be scanned with shorter scan times (fewer camera translations). Two built-in FOVs
tested were 37.4 mm (one camera translation) and 49 mm (two camera translations).
Regarding magnification, the photon count rate was adjusted to ensure statistical
assessments were not affected. Thus, the same photon count rate was achieved
before and after an upgrade.
Figure 3.1: A diagram of the MARS scanner internals. The gantry houses the X-ray
source and detector and rotates around the sample (0-360o), as the sample moves along
the z-axis. A continuous helical scan is employed. Camera translation can move along the




3.1.2 Modulation transfer function (MTF)
Spatial resolution is determined by the characteristics of the imaging system (pixel
size, reconstruction kernel, hardware properties) and is defined as the ability to dis-
tinguish two objects (Verdun et al., 2015). Also, spatial resolution can be defined
by how blurred a bright point on a dark background is imaged, known as the point
spread function. Determining spatial resolution includes: measuring contrast of ma-
terial to background, the MTF from the measured edge of a cylinder, and distortion
(Suetens, 2017). The current chapter used MTF to make an objective resolution es-
timation (see fig. 3.2). MTF is often indicated by line pairs per millimetre (lp/mm)
at a specified amplitude (%), the standard being at 10% MTF, which can then be
converted to the more intuitive physical domain: spatial resolution in micrometres
(µm).
Figure 3.2: Example of 1-dimensional MTF curve which describes the signal response of
the system at a given spatial frequency. MTF provides a measure of contrast transfer from
the object plane to the image plane at a specific resolution (Verdun et al., 2015).
3.1.3 Noise
The emission and detection of X-rays is stochastic in nature; that is, several random
processes are involved, thus, noise will always be present. Noise within CT images
are unwanted voxel value changes in an otherwise homogeneous image. The current
thesis dealt with a photon-counting detector where every pixel is behaving as an
individual detector. Therefore, at the detector level, image signal (S) is directly
linked to the number of photons (N) detected. Noise (σ) is considered stochastic
fluctuations around the mean value of a pixel and is distributed by Poisson’s law.
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Thus, σ is equal to
√










Flat-field images are projection images captured without the object in front of
the X-ray source. Flat-field images were acquired for every scan to correct for fixed-
pattern noise (FPN). FPN include pixels that consistently count too low/high and
“wrinkle”-like patterns that are often observed at the detector level, caused by in-
homogeneity within the CdTe/CZT sensor layer. Such pixel-to-pixel non-uniformity
variations are normalised using the flat-field images to equalise the number of counts
detected. This process works to minimise noise in the reconstruction of MARS im-
ages. Moreover, Medipix3RX is a low count-rate detector, which has the ability to
eliminate electronic noise or leakage current and improve SNR and spectral separa-
tion at high resolution (Ballabriga et al., 2013; Willemink et al., 2018).
The photons counted (N), or flux, can also be affected when the MARS camera
is upgraded. N will either decrease or increase, which affects the SNR. Therefore,
performance of the three-chip Medipix3RX detector cannot be directly compared to
the single-chip detector. The baseline values established by the single-chip detector
are used to assist in indicating the presence of a fault following an upgrade.
3.1.4 Material identification
Spectral photon-counting CT provides energy and material images. In order to draw
links between energy image quality and material information obtained, additional
tools are required. Currently, the in-house tool described in the paper Raja et al.
(2018), was used to assess the performance of material images, and is referred to as
material identification. Material identification gives a baseline assessment similar
to what we can achieve with SNR and spatial resolution, in terms of performance
quality.
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3.2. Materials and methods
For more information on material decomposition and material identification anal-
ysis, refer to Chapter 2, section 2.2.3. Like spatial resolution, many factors influence
material differentiation success (protocol design, detector efficiency, scanner hard-
ware). Therefore, the purpose of assessing material identification as an image quality
indicator is to ensure the stability of identification when using the same protocol.
The accuracy of identification is not relevant in the current chapter. In later chap-
ters, material identification is used to examine the protocol design for a specific
preclinical application or question.
3.2 Materials and methods
3.2.1 MARS imaging
The camera axial and tangential offsets (-2.4 mm and -0.12 mm, respectively) of
the single-chip MARS camera were tested first. Camera offsets either side were
investigated to find more optimal values. The MARS scanner version with the
single-chip camera has a default FOV of 32 mm. Default factory FOVs for the
three-chip camera version of the scanner are 37.4 mm (one camera translation) and
49 mm (two camera translations). Table 3.1 summarises the parameters employed
for all QA tests.
Table 3.1: Summary of scanning protocol for QA testing. SDD and SOD are Source
to detector distance and source to object distance, respectively. *The tube current was
increased from 24 µA to 26 µA to maintain the same mean photon count rate for single-
and three-chip cameras.
Protocol parameters MTF phantom Four-hole phantom Multi-material
phantom
Scan type Continuous motion Continuous motion Continuous motion
Tube voltage 118 kVp 118 kVp 118 kVp
Tube current 26 µA 26 µA 26 µA
Exposure time 220 ms 220 ms 220 ms
SDD, SOD 250 mm, 200 mm 250 mm, 200 mm 250 mm, 200 mm
Field of view 37.4 mm, 49 mm 37.4 mm, 49 mm 37.4 mm, 49 mm
Circular projections over 720, 720 720, 720 720, 720
360o, flat-fields
Voxel size (isotropic) 0.09 mm 0.09 mm 0.09 mm
X-ray filtration 3.8 mm (2 mm Al + 3.8 mm (2 mm Al + 3.8 mm (2 mm Al +
1.8 mm Al intrinsic) 1.8 mm Al intrinsic) 1.8 mm Al intrinsic)
Energy thresholds 30, 45, 60, 78 keV 30, 45, 60, 78 keV 20, 27, 45, 69 keV
Scan length 7 mm 7 mm 15 mm
Camera axial offset -2.3, -2.4, -2.7 mm -2.4 mm -2.4 mm
Camera tangential offset -0.12, -0.16, -0.2 mm -0.16 mm -0.16 mm
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3.2.2 MTF phantom analysis
Using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA), the reconstructed energy data were converted to 32 bits and
rescaled into linear attenuation values for the purpose of an appropriate scale to
analyse. The reconstructed dataset was sorted into four energy bins (30-45, 45-60,
60-78, and 78-118 keV). Each energy bin was saved in Tagged Image File (TIF)
format and analysed separately due to the energy dependency of spatial resolution.
The current thesis used the standard measurement; lp/mm at 10% MTF, calcu-
lated using the 32 mm diameter polymethyl methacrylate (PMMA) phantom shown
in Figure 3.3a. Figure 3.3b and 3.3c demonstrate how MTF was calculated from
one axial slice in energy bin 30-45 keV. Lp/mm at 10% MTF was converted into
the more intuitive physical domain of µm by multiplying the reciprocal lp/mm res-
olution value by 1000, and dividing by two. For example, 2.3107 lp/mm at 10%
MTF converts to 216.4 µm spatial resolution. Spatial resolution of the system was
calculated from the mean of the four energy bins.
(a) (b) (c)
Figure 3.3: (a) 32 mm diameter PMMA MTF phantom. (b) Illustration of one dimensional
profiles through phantom centre. Energy image slice from 30-45 keV, reconstructed with
90 µm voxel size (isotropic). Scale bar displays linear attenuation. Aligning and averaging
several edge profiles produces the edge response function (ERF). Differentiation of the
ESF provides the system line-spread function (LSF). (c) MTF curve obtained by discrete
Fourier transformation of the LSF. 10% MTF value in lp/mm indicated.
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3.2. Materials and methods
3.2.3 Four-hole phantom analysis
SNR was measured using the custom-made PMMA phantom shown in Figure 3.4a,
referred to as the Four-hole phantom. The mean µ in a homogeneous region was
divided by the standard deviation (σ) of that same region. Using the equation 3.2,
five regions within one slice were measured then averaged to calculate SNR of that
slice (see fig. 3.4b and 3.4c). Several slices were used to find the average SNR for
all energies.








Figure 3.4: (a) 37 mm diameter PMMA Four-hole phantom has four 15 mm cylindrical
holes along its length. (b) Four-hole phantom in the in-house program with manual selec-
tion of the phantom for SNR analysis leaving an air boundary (c) Once the four holes are
detected by the in-house program, five regions of interest, indicated by white squares (cen-
tre, top, bottom, left, and right) were used for the calculation of mean linear attenuation,
µ, and standard deviation, σ.
3.2.4 Multi-material phantom analysis
The multi-material phantom enables quantitative assessment of material identifica-
tion. The imaging protocol designed for this phantom was established previously
by a colleague using K-edge imaging of multiple high-Z materials for MARS-11,
single-chip camera (Moghiseh, 2018). The multi-material phantom contained six
materials: a major component of bone called hydroxyapatite (HA; QRM Quality
Assurance in Radiology and Medicine GmbH, Mhrendorf, Germany), soft tissue-
equivalent (water), fat-equivalent (lipid), gadolinium (Gd; gadopentetate dimeglu-
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mine, Berlex Laboratories, Wayne, NJ, USA), iodine (I; Omnipaque, GE Healthcare,
Princeton, NJ, USA), and gold chloride (Au; supplied by the MARS team). All vials
were inserted into a custom-made PMMA phantom with a total of 12 circular in-
serts, 6 mm in diameter (see fig. 3.5). Refer to Chapter 2 for details on material
decomposition and material identification analysis.
(a) (b)
Figure 3.5: (a) Custom-made, 32 mm diameter, multi-material PMMA phantom (a) and
an axial schematic of the phantom (b). The phantom contains 200µL Eppendorf PCR
tubes of I (4.5, 9, and 18 mg/mL), AuCl (2, 4, and 8 mg/mL) , HA (200, 800 mg/cm3),
and Gd (2 and 8 mg/mL), and one vial of lipid (L) and water (W).
3.3 Results
3.3.1 MTF phantom
Following installation of the three-chip camera, spatial resolution degraded by 133.8
µm. An axial offset of -2.4 mm and tangential offset of -0.16 mm improved spatial
resolution for the three-chip camera, as shown in Figure 3.6. One slice from energy
bin one (30-45 keV) for single-chip, three-chip with incorrect camera offset, and
three-chip camera with correct camera offset are shown in Figure 3.7. Image quality
is visibly affected by the incorrect camera offset.
Figure 3.8 illustrates QA testing (spatial resolution shown) during the months
of April-August 2018. Camera translational offset values were adjusted in April to
improve image quality following another removal and new placement of the camera.
Near baseline spatial resolution for the three-chip camera (obtained in fig. 3.6) was
maintained post April for the following months shown.
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3.3. Results
Figure 3.6: Spatial resolution in µm for energy bin one (30-45 keV) is displayed on the
y-axis. The x-axis displays the camera tangential offset position, distance in mm from the
default central position (0 mm). 32 mm FOV was employed. The orange line represents
the baseline spatial resolution established using the single-chip camera. The axial offset
used was -2.4 mm for all scans unless specified otherwise.
Figure 3.7: (a) Axial slice obtained by the single-chip camera. (b) Three-chip camera scan
shows degradation in image quality. A ring artifact indicates geometric error. (c) Three-
chip camera scan with geometric errors minimised via adjustment of camera translational
offsets.
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Figure 3.8: An example of QA in mid-2018 months, image quality in April was compro-
mised due to disturbance to the camera offset parameters. The baseline or benchmark
resolution is represented by the orange line, which was established for the three-chip cam-
era, and shown to be maintained in the following months.
Under ideal conditions (correct camera offset), the MTF phantom was scanned
with a FOV of 37.4 mm and 49 mm. A resulting slice from each scan in the first
energy bin is shown in Figure 3.9. Spatial resolution (30-45 keV) was plotted for the
two FOV scans, along with the single-chip camera baseline (see fig. 3.10). It was
found that 49 mm FOV had superior mean spatial resolution, compared to 37.4 mm
FOV. Further adjustment to the FOV or camera offset parameters will use the 49
mm FOV mean spatial resolution as the new benchmark for the three-chip camera.
Figure 3.9: Slice 78 in energy bin one (30-45 keV) of the MTF phantom, scanned with 49
mm FOV and 37.4 mm FOV.
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3.3. Results
Figure 3.10: Energy bin one (30-45 keV) spatial resolution in µm as a function of energy
bin for three different FOVs.
3.3.2 Four-hole phantom
The Four-hole phantom was scanned using two FOVs, one slice from each scan is
shown in Figure 3.11. The SNR for energy bin one (30-35 keV) was plotted for the
two FOV scans and single-chip camera baseline. It was found that 49 mm FOV had
superior mean SNR, compared to 37.4 mm FOV (see fig. 3.12). This value for SNR
can be used as the new benchmark for future three-chip camera scans.
Figure 3.11: Slice 78 in energy bin one scanned with 49 mm FOV and 37.4 mm FOV.
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Figure 3.12: SNR for energy bin one (30-45 keV) for three different FOVs. A small
increase in SNR is observed for the protocols with 37.4 FOV and 49 FOV, compared to
the baseline.
3.3.3 Multi-material phantom
Optimisation of the single-chip camera produced the material identification chart
shown in Figure 3.13 (Moghiseh, 2018). The scanning protocol developed by Moghiseh
(2018) was employed in the current chapter. Thus, it is worth noting that QA re-
sults acquired may not be comparable to the results obtained by Moghiseh (2018),
since the protocol was optimised for a single-chip camera. The goal for optimisation
of the three-chip camera was to obtain the best possible image quality with this
particular camera.
Figure 3.13: Reference material identification chart for the single-chip camera. Baseline




One reconstructed slice of the multi-material phantom for each FOV is shown in
Figure 3.14. The spectral response for iodine, gadolinium, HA, and gold are shown
in Figure 3.15. The spectral responses are comparable, since the only variable
that differs is FOV. The HU values are greater for most spectral response trends
for the 49 mm FOV scan, compared to 37.4 mm FOV. For example, there is a
difference of approximately 50 HU for Gd 8 mg/mL and I 18 mg/mL. Linearity of
the spectral response for each material is plotted in Figure 3.16. R2 describes the
linear relationship between concentration and attenuation. An R2 value close to 1
indicates a relationship between attenuation and concentration has been established,
which is the case for both FOVs. However, seven R2 values of the 37.4 mm FOV
scan are further from 1, compared to 49 mm FOV.
Figure 3.14: Slice 78 in energy bin one (30-45 keV) of the multi-material phantom, scanned




Figure 3.15: The spectral response of each material plotted for 37.4 mm FOV (solid line)
scan and 49 mm FOV (dashed line) scan. HA (c) and iodine (a) follow the same trend and
possess similar HU values in both scans. A difference in trend and HU values is observed
in lower concentrations, for example I 4.5, Gd 2, and Au 2 mg/mL. The errors in HU are





Figure 3.16: All values of R2 are 0.99, unless stated otherwise on the graphs above. 37.4
mm FOV (solid line) scan is compared to 49 mm FOV (dashed line). All R2 values were
found to be 0.99, unless stated otherwise. The linear relationship is the basis of calculating
unknown concentrations of the materials of interest, in this case, HA, Au, I, and Gd.
The mass attenuation coefficients, obtained from the analysis of the multi-
material phantom scans, were used to apply MD to the multi-material phantom.
The MD results were visualised using MARS Vision, as shown in Figure 3.17. The
same post processing (transfer functions) for visualisation of material was applied
to 37.4 mm and 49 mm FOV scan. The MD results showed 49 mm FOV provides
better visualisation compared to the 37.4 mm FOV scan. For example, the red cir-
cle in Figure 3.17 illustrates there is a clear difference in material identification of
lower concentrations of Au and I. Figures 3.18a and 3.18b display material identifi-
cation charts for 37.4 mm and 49 mm FOV, respectively. The larger 49 mm FOV
provided greater material identification success compared to 37.4 mm FOV. For ex-
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ample, 42.5% of voxels within the 2 mg/mL of Gd vial were identified as Gd for 37.4
mm FOV scan, and 77.8% for 49 mm FOV. Identification of Au also improved for
each concentration. The final material identification results correlated well with the
higher SNR, spatial resolution, and attenuation obtained for 49 mm FOV.
Figure 3.17: Material decomposition visualised using MARS vision for 37.4 mm and 49
mm FOV. The spectral data have been treated with equal post processing parameters,
including smoothing of the data and visualisation of concentration via transfer functions.
The observed difference is circled; the lower concentrations of Au and I have some identi-





Figure 3.18: Assessment of material images by looking at material identification, shown
for 37.4 mm (a) and 49 mm FOV (b).
3.4 Discussion
The aim of the current chapter was to maintain image quality following a hardware
upgrade, to ensure stability and thus, reliability of biological experiments. QA scans
were performed using custom-made phantoms. Results from the MTF phantom re-
vealed image quality degraded; spatial resolution decreased by 133 µm. Degradation
in image quality was due to camera offset error. Therefore, different camera offset
(axial and tangential) values were employed to examine different outcomes of spatial
resolution. An axial offset of -2.4 mm and tangential offset of -0.16 mm provided
comparable spatial resolution to the single-chip camera’s baseline spatial resolution.
The optimal camera offsets were employed in QA scans of two FOVs; 37.4 mm and
49 mm. The FOV of 49 mm provided greater mean spatial resolution and SNR,
compared to 37.4 mm FOV. The length of the MARS camera, three chips of dimen-
sion 14 mm x 14 mm (excluding chip gap), is approximately 42 mm. Therefore, 37.4
mm FOV required only one camera translation, while 49 mm FOV required two
camera translations. For two camera translations, a large part of the image contains
voxels that gain two-fold the data available. Thus, greater spatial resolution and
SNR is acquired for two camera translations.
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Two assumptions are made when computing MTF: 1) the systems response re-
mains the same, whether measured at the image periphery or centre and 2) the
output signal remains within an optimal range, in terms of HU (Boone et al., 2012).
For example, estimating MTF using high-Z material will generally yield a signal
above the optimal range and will therefore lead to incorrect estimations of spatial
resolution. The two assumptions are approximately met by the filtered back pro-
jection reconstruction technique. However, iterative reconstruction (IR) techniques
exhibit stronger non-linear properties which has been observed in extant research as
contrast dependency of the resolution (Hsieh et al., 2013; Thibault, Sauer, Bouman,
& Hsieh, 2007; Vaishnav, Jung, Popescu, Zeng, & Myers, 2014). MARS scanners
employ an IR technique, as this technique has been reported to provide decreased
image noise and increased SNR (Bittencourt et al., 2011; Leipsic et al., 2010; Spears
et al., 2014; Thibault et al., 2007). In the current chapter, assumption 1) was met
by taking measurements from the same location in different slices to obtain an MTF
that could be used to compare. Furthermore, PMMA material was used to obtain
the output signal for calculating MTF. Future QA of the MARS scanner may ben-
efit from overcoming difficulties in estimating resolution for iterative reconstruction
techniques by using an adapted metric. For example, Target Transfer Function can
characterise the resolution of a system even when contrast dependency and noise is
present (Ott et al., 2014; Richard, Husarik, Yadava, Murphy, & Samei, 2012). Re-
search has demonstrated Target Transfer Function performing full characterisation
of resolution of CT systems dealing with iterative reconstruction techniques (Brun-
ner, Abboud, Hoeschen, & Kyprianou, 2012; Ott et al., 2014).
The effect of image quality on a third variable, material identification, unique to
energy-resolving detectors was demonstrated. Material identification stability was
compared for a 49 mm and 37.4 mm FOV. The FOV of 49 mm provided material
identification success close to that of the benchmark established by the single-chip
camera. To fully understand the role that the number of camera translations play,
and the influence of data overlap on image quality and material identification, it is
recommended that future studies investigate three camera translations compared to
two and one camera translations. Furthermore, investigation of optimal overlap if
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3.4. Discussion
more than one camera translation is employed is necessary. A second camera up-
grade and time constraints precluded further FOV/camera translation investigation
of the three-chip camera in the current PhD studies. Moreover, the direction in
which image quality assessment is heading within the MARS team is automation of
QA procedures. For example, designing different modules within the same phantom
which can provide MTF, SNR, and material identification information in a single
scan, and the development of software/in-house programs that can assess each of
the modules simultaneously. What requires several scans now, will only require a
single scan in the future. Figure 3.19 demonstrates the use of a line phantom for
semi-automatic calculation of the camera axial and tangential offset parameters, in
contrast to “trial-and-error” methods conducted at the time of the current study.
Figure 3.19: Projection image sourced from the Medipix3RX detector with three detector
chips. The image shows a custom-made phantom has been scanned which enables the
tangential offset (TO) and axial offset (AO) to be found. This approach will replace the
slow “trial and error”method employed at the time of writing this thesis. Image credit:
Neryda Duncan, PhD student, thesis due to be submitted Jan 2021.
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3.5 Summary
• The Medipix3RX camera was upgraded from one-chip to three-chips, which
resulted in decreased image quality. Image quality was improved by adjusting
camera mount axial and tangential offsets until MTF values were close to the
baseline established by the single-chip camera.
• Two FOVs that required one and two camera translations were examined.
SNR, MTF, and material identification were assessed. Two camera transla-
tions meant a large part of the image contained voxels that gained two times
the data available, therefore more signal, greater SNR and spatial resolution.
• Material image performance improved with greater spatial resolution as better
spatial resolution and SNR enabled the spectral response and linearity of the
spectral response to be established more accurately.
• Target Transfer Function may provide more accurate characterisation of the
spatial resolution, compared to MTF, for iterative reconstruction techniques.
• The future direction of QA procedures will involve the development of an
automated process and a phantom and software that provides MTF, SNR,
and material identification information, simultaneously.
• Regular QA testing ensures uniformity of the system over time which is impor-
tant for proof-of-concept studies surrounding material identification, whereby





Quantitative imaging of ex-vivo
pulmonary tuberculosis using
non-specific contrast material
The current chapter is the first step in an approach to provide more or new informa-
tion for the detection of infectious diseases with spectral photon-counting CT imag-
ing. Pulmonary tuberculosis (TB) was chosen as a representative candidate due to
the global burden of disease TB poses; that is, the sum of mortality, morbidity, and
other impact indicators of TB are significant (World Health Organization, n.d.).
This proof-of-concept, ex-vivo study demonstrated that spectral photon-counting
imaging, using the MARS scanner, can identify/locate and quantify contrast ma-
terial within pulmonary tuberculosis (TB) lesions. My contribution to the study
included study design, optimisation of the MARS imaging protocol, data collection
and analysis, and interpretation of results. Concepts presented here contributed to a
publication by Ortega-Gil, Vaquero, Gonzalez-Arjona, Rullas, and Muñoz-Barrutia
(2019), and a manuscript in preparation, which I will be the primary author.
The aim of the current study was to validate MARS images using a standard
micro-CT subsystem, optimised for soft-tissue imaging. Alongside the micro-CT
imaging study, histology is used to establish tissue segmentation thresholds. His-





According to the World Health Organisation, mycobacterium tuberculosis (TB) is
a worldwide health problem, with 10 million new TB cases and 1.3 million deaths
recorded in 2017 alone (World Health Organization, n.d.). Drug resistant TB strains
remain a public health crisis threat and account for 3.3% of TB-related deaths (Dye,
2006; Dye, Scheele, Pathania, Raviglione, et al., 1999; Shah et al., 2008). Extensive
efforts to curb TB and TB drug resistance has resulted in a decline in TB incidence
of about 2% per year. However, decreasing incidence rates must accelerate in order
to reach targets set by the Sustainable Development Goals (SDG) (World Health
Organization, n.d.). There is a need to improve TB diagnosis and therapy.
Traditional diagnostic modalities employed for TB include microbiology, mi-
croscopy, and molecular techniques (nucleic acid testing or acid-fast staining), all of
which require biological samples (blood, stool, or sputum cultures) (Cadena, For-
tune, & Flynn, 2017). Biological samples may not accurately reflect the local biology
at the site of infection, thus, are often not sensitive enough as a stand alone diag-
nostic test (poor sensitivity: 45-85%) (Lawn, Kerkhoff, Vogt, & Wood, 2012; Tucker
et al., 2018). Furthermore, the requirement of sputum cultures limits or delays di-
agnosis because TB bacterium is difficult and slow to cultivate ex-vivo (2-8 weeks)
(Ordonez et al., 2019). Biopsies (removal of tissue) are often the last resort for
unequivocal diagnosis. However, biopsies are invasive, generally limited to the most
accessible lesion, prone to sampling error, and fail to capture the heterogeneous na-
ture of TB infection. Thus, similar to biological samples, biopsies may only provide
a localised indication of lesion composition, they do not report on the entire disease.
Clinically available imaging can provide whole tissue assessment and have a role
depending on the patient’s clinical profile. Limitations of clinically available modal-
ities are described briefly in Chapter 1, Section 1.2. Ultrasound, MRI, and X-ray
imaging are based on anatomical changes; changes that are often delayed relative to
disease progression at the molecular level. The current chapter presents first time
MARS imaging of contrast-enhanced TB lesions as a way of illustrating cutting-edge
translational spectral photon-counting CT imaging that has the potential to assist
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already existing modalities. In addition, new information will be acquired, including
non-invasive, quantitative tissue-specific images at high resolution. Moreover, if a
high-Z material is functionalised with an anti-tuberculosis drug molecule, quantita-
tive assessment of drug delivery and therapy could be made possible using spectral
imaging.
MARS imaging was compared to imaging of the same mice lungs with a pre-
clinical high-resolution micro-CT subsystem (SuperArgus scanner, Sedecal Molec-
ular Imaging, Madrid), optimised for soft-tissue imaging tasks (Ortega-Gil, 2019).
Iodine-based contrast material was employed as it is an easily accessible, low cost,
standard CT contrast agent. A second high-Z contrast material was imaged; silver
nitrate (AgNO3), to demonstrate that enhancement of soft tissue can be achieved
by multiple, non-specific contrast materials. Furthermore, research has shown silver
has antimicrobial properties (Jeyaraj et al., 2013; J. S. Kim et al., 2007; Sung et al.,
2009), and has the potential to be used in the future as an inhaled contrast agent at
low doses for targeted lung imaging. Moreover, the energy resolution of the MARS
scanner is shown to identify materials with small differences in atomic number (in
a single exposure), a pitfall associated with DECT imaging.
4.2 Materials and methods
Sections 4.2.1, 4.2.2, and 4.2.3.1 are performed by collaborator Dr Ana Ortega-Gil
(Ph.D, Universidad Carlos III de Madrid, Spain) (Ortega-Gil, 2019; Ortega-Gil et
al., 2019).
4.2.1 Lung sample preparation
The current research was based on excised whole organs from procedures approved
by the Animal Experimentation Ethics Committee of Hospital General Universi-
tario Gregorio Maran, Madrid, Spain and performed according to EU directive
2010/63/EU and national regulations (RD 53/2013).
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Mouse lung tissue examined were from four females of the C57BL/6J strain.
Two of the mice were inoculated with virulent Mycobacterium tuberculosis (TB)
H37Rv strain via exposure to aerosol infection (dose 100 colony forming units) at
the age of 8-12 weeks. All four animals were euthanised eight weeks following the
intra-tracheal insult using CO2 gas. At that time, chronic TB was established, and
well-formed lesions were present (animals were euthanised prior to the development
of calcification). Prior to lung tissue extraction, the animals received 15 mL of 10%
formalin through the trachea. To retain the formaldehyde solution within the lungs,
a thoracic opening was made, and the lungs were closed at the top and bottom by
a thread. Once fixed, the lungs were extracted and placed into 10% formaldehyde
for at least 18 days to ensure deactivation of the TB infection.
4.2.2 Lung sample staining
The tissue samples underwent a fixation procedure in a graded dehydration series
of ethanol protocol (graded ethanol concentration fixation: GECF) prior to stain-
ing with contrast. The purpose of the GECF protocol, described in e Silva et al.
(2015), was to increase the absorption of contrast. One healthy mouse lung and
one TB-infected lung were immersed in iodine (Sigma-Aldrich Co.) in 3% weight
per volume ethanol solution. The two remaining samples were immersed in silver
nitrate (AgNO3; Sigma-Aldrich Co.) in 3% w/v ethanol solution. The lungs were
kept inflated at a constant pressure of 20 cmH2O during the GECF and staining
processes to prevent abrupt shrinkage and ensure homogeneous uptake. The stained
lung samples were stored within 70% ethanol (see fig. 4.1) and could be kept without
discolouring for up to four months at room temperature. Cotton gauze was used to
secure the lungs while in the ethanol solution. The samples in ethanol were scanned




Figure 4.1: AgNO3 stained lungs are visibly darkened by the contrast material (a), and I
stained lungs (b). Lungs are placed in 70% ethanol to prevent tissue dehydration.
Following MARS scanning of the lungs in ethanol, the iodine stained lungs were
fixed in paraffin. Prior to fixation, the lungs were submerged in iodine contrast for
2 hours. Paraffin fixation provides the opportunity to cut the lungs for histological
slides which would correspond with MARS image slices. A tinfoil layer was used
to cover the bottom of the paraffin cassette, which measured 5 cm (w) x 7 cm (l)
x 1.5 cm (d). A total of 104 mL of heated paraffin was used to embed the TB
infected and healthy lung samples, separately. Paraffin blocks were left to cool
and harden for 24 hours before imaging. The purpose of paraffin fixing is to have
direct comparison between micro-CT images and MARS images for tissue analysis.
Furthermore, fixation enables histological analysis, which can be used to enhance
our understanding for tissue segmentation and tissue quantification (Ortega-Gil et
al., 2019). Time constraints precluded the use of histology in the current chapter;
however, histology will be included in the manuscript in preparation.
4.2.3 Lung imaging
4.2.3.1 SuperArgus micro-CT
The acquisition protocol was optimised (in terms of beam conformation) for en-
hanced soft-tissue contrast (Ortega-Gil, 2019). The SuperArgus micro-CT subsys-
tem (Sedecal Molecular Imaging, Madrid) is based on an energy-integrating detec-
tor. Pulmonary imaging tasks require copper filtration with a peak voltage of 65∼70
kVp. Because this protocol is also used for in-vivo imaging, a compromise between
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image resolution and total acquisition time was taken into consideration.
4.2.3.2 MARS imaging
The PMMA phantom holder contained 200 µL vials of water, lipid, iodine-based so-
lution (2.25, 4.5, 9, and 18 mg/mL), and silver-based solution (2, 4, and 8 mg/mL)
for calibration purposes (see fig. 4.2). For an equivalent acquisition protocol to
that of the SuperArgus scanner, the MARS scanner X-ray tube was operated at a
constant peak voltage of 60 kVp and tube current of 90 µA, with 3.8 mm total Al
X-ray filtration. The K-edge of silver (25.5 keV) was close to the K-edge of iodine
(33.2 keV), however, appropriately selected energy thresholds allowed for the iden-
tification of iodine and silver, simultaneously. After analysis of theoretical energy
thresholds via NIST data (Chapter 2, Section 2.2.1), the following energy thresholds
in CSM were selected: 20, 27, 34 and 45 keV. Summary of the imaging protocols
employed for the SuperArgus and MARS scanner are shown in Table 4.1.
The mass attenuation values were obtained from analysis of the calibration phan-
tom vials using an in-house program. MD was applied to the energy images of the
calibration phantom and material identification assessment performed. All four ex-
cised lung samples in ethanol were scanned with the MARS scanner. Since iodine is
a common contrast agent for CT imaging, the iodine stained lungs were used in the
preliminary study of paraffin fixation, and used for comparison between the MARS
scanner and micro-CT. Tissue analysis was performed on the paraffin-fixed lung.
(a) (b)
Figure 4.2: Calibration phantom (a) and an axial schematic of the phantom (b). The
phantom contains 200µL Eppendorf tubes of AgNO3 (2, 4, and 8 mg/mL), I (2.25, 4.5, 9,
and 18 mg/mL), lipid (L), and water (W).
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Table 4.1: Summary of acquisition parameters for pulmonary task using MARS-11 (V5.1
(2016) S/N:11) and micro-CT system.
Protocol parameters MARS spectral CT SuperArgus micro-CT
Scan type Continuous motion Step and shoot
Tube voltage 60 kVp 69 kVp
Tube current 90 µA 420 µA
Exposure time 220 ms 50 ms
Magnification 1.25 3.1
Field of view 32 mm 93.1 x 58.9 mm
Circular projections over 720, 720 514, 514
360o, flat-fields
Voxel size (isotropic) 0.09 mm 0.088 mm
X-ray filtration 3.8 mm Al (2 mm Al + 0.2 mm Cu + 1.8 mm Al
1.8 mm Al intrinsic) intrinsic
Energy thresholds 20, 27, 34, 45 keV Not applicable
Total acquisition time 30 min 7 min
Detector model CZT-Medipic3RX Dexela 1512
Reconstruction algorithm mART FDK cone beam analystic
4.2.4 Tissue analysis
4.2.4.1 SuperArgus micro-CT
Segmentation of the lung damage caused by TB in standard PET/CT and CT images
was performed using thresholding methods, such as that described in R. Y. Chen et
al. (2014). An automated algorithm was developed to extract the volume of diseased
lung. Histograms of lung voxels in HU were exported and revealed prominent abnor-
mal densities which appeared to be associated with disease. A similar thresholding
methodology was later applied in Ortega-Gil et al. (2018), where accurate CT seg-
mentation of the disease-associated tissue could be aided by the use of histological
analysis. In the current study, for the SuperArgus micro-CT system, histograms of
the lung voxels were exported for the healthy lung. The greatest density in terms
of HU within the healthy lung dataset was found and a 5% margin was added. The





MARS scanners provide energy and material-specific information, thus a slightly
different method was employed for tissue analysis. Energy bin one (20-27 keV)
was used to segment out the whole lung tissue by manual selection in axial slices.
Energy bin one was used as lower energy photons contribute more to CNR than
higher energy photons. Iodine identified in voxels outside the region established
using the energy images was assumed to be misidentification due to artifact or
misidentification of paraffin as iodine and was excluded. Similarly to the micro-CT
system, histograms of the lung voxels in terms of iodine concentration (mg/mL)
were exported. The same method of using the healthy lung dataset to find the
threshold between healthy and disease-associated tissue was implemented. Volumes
were calculated by summing the volume of voxels whose values fell within the selected
thresholds within the overlaid region of interest.
4.3 Results
4.3.1 Differentiation of iodine and silver with MARS imaging
Figure 4.3 shows one reconstructed slice of the calibration phantom in each energy
bin. The unique spectral response for silver and iodine are included in Figure 4.4a.
The K-edge of silver, 25.5 keV, was detected as a peak in attenuation in the second
energy bin (27-34 keV) for each concentration of silver. Similarly for iodine, a peak
in attenuation was observed in energy bin three (34-45 keV). Figure 4.4b and 4.4c
display the linearity of attenuation for silver and iodine, respectively. The linearity
established for silver material showed a decrease in R2 value compared to iodine.
However, as shown in Chapter 3, detector responses could not fully predict material
image performance. Thus, material identification and quantification assessment is
necessary.
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Figure 4.3: MARS energy images of the calibration phantom detailed in Figure 4.2.
(a)
(b) (c)
Figure 4.4: (a) Spectral response of the detector for all calibration vials (excluding water
and lipid). Enhancement of attenuation is observed (for all concentrations) in energy bin
3 (34-45 keV) and energy bin 2 (27-34 keV), which indicates the K-edges of iodine and
silver, respectively. The standard errors for each data point are in the range of 1-10 HU.
(b) Silver and (c) iodine linearity of attenuation is established. The result of the linear
regression is displayed on the graph. R2 = 0.99 for all energy bins of iodine.
Figure 4.5 illustrates the detection of iodine in the iodine-based solutions, silver
in the silver-based solutions, water, and lipid. The phantom material identification
chart is displayed in Figure 4.6. Material identification success is greater than 99.5%
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for all iodine concentrations, that is, 99.5% of voxels within the iodine vials were
correctly identified as iodine. In contrast, some misidentification occurred in the
silver nitrate 2 and 4 mg/mL. Iodine produced greater HU compared to silver,
as shown by their linearity trends. However, Moghiseh (2018) reported that 80%
identification success or greater is considered a good material image performance.
Figure 4.5: Material decomposition of the calibration phantom viewed using MARS Vi-
sion. Four material datasets shown; iodine (orange), lipid (beige), silver (white), and
water (blue).
Figure 4.6: Misidentification chart shows lipid (purple), silver nitrate (solid grey), water
(blue), and iodine (striped orange). For all concentrations of iodine, greater than 99%
successful identification was achieved. At 2 mg/mL of silver nitrate, there is a 85.0%
identification success.
Each calibration vial was measured in the MD and compared to the actual known
concentration, as shown in Figure 4.7. The comparison provides validation regard-
ing contrast measured in the lung sample MD. The mean of the measured silver was
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consistently less than the actual concentration. The possible reasons responsible for
the discrepancy in silver measurements are that the samples provided may have un-
dergone some precipitation, the “known” concentration was not correct (supplied by
my collaborator), and finally, image artifacts can affect the measured concentrations.
Protocol design is a major factor that influences the material identification and
quantification. The protocol used in the current study, although considered sufficient
for distinguishing silver and iodine, favours the identification and quantification of
iodine-based contrast. However, there is a linear relationship between the measured
and known concentration of silver (R2 = 0.99), therefore, if required, a correction
can be added in future quantitative analysis. In the current study, iodine is used
for volume quantification for the MARS scanner vs micro-CT. The measured iodine
presented comparable results, thus confidence that the stained concentration and
measured concentration will be accurate.
Figure 4.7: Measured concentration from MD versus known concentration. Iodine shows
comparable values; therefore, we can be confident that what is measured in the biological
specimen will be comparable to what is actually present in the organ. Silver shows some
disparity, due to incorrect linearity of attenuation. Future studies may look at the influence
of employing more concentrations of silver. Due to the limited supply of silver nitrate,
only three concentrations were available.
4.3.1.1 Lungs in ethanol
Healthy and TB-infected lung tissue (in ethanol) presented whole organ uptake of
contrast material (see fig. 4.8 and 4.9). Higher concentrations of iodine were found
proximal to the TB lesions. Whole organ iodine and silver uptake was quantified
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from MD images: the TB-infected lungs presented a 2.7-fold increase in iodine
uptake, and 1.3-fold increase in silver uptake, compared to healthy lung tissue in the
same staining. The MD images of the lungs in ethanol demonstrated two outcomes;
firstly, multiple high-Z materials can be used to enhance TB lesions, and secondly,
MARS imaging is capable of separating high-Z materials with small differences in
atomic number, simultaneously.
Figure 4.8: Healthy and TB-infected excised mouse lungs scanned together using the
MARS scanner. The colour bar displays iodine concentration. Water, lipid, and energy
datasets are not shown. The maximum concentration of iodine uptake within the healthy
lung was used as an indicator of diseased associated tissue in orange. Dark blue shows
an increased uptake of iodine occurred in the heart and trachea, and proximal to the
disease associated tissue. Dark blue proximal to the diseased associated tissue may suggest
inflammation caused by the disease, since this is absent in the healthy lung lobes.
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Figure 4.9: Similar to Figure 4.8, except with silver contrast. Maximum silver uptake,
shown in white, was observed in the trachea of the healthy lung, whilst the lung lobes
appear to have taken up the least silver. Maximum silver uptake within the TB-infected
lungs occurred in the trachea and diseased associated tissue. Dark blue shows an increased
uptake of silver proximal to the disease associated tissue, suggesting inflammation caused
by the disease, since this is absent in the healthy lung lobes.
4.3.2 MARS scanner vs micro-CT
Using MARS Vision, Figure 4.10 displays 3D visualisation of the data obtained
by micro-CT 4.10a, 4.10b, and data obtained by MARS spectral CT 4.10c, 4.10d.
Compared to the lungs in ethanol scan (see fig. 4.8 and 4.9), there was a visible re-
duction in tissue volume due to the paraffin fixing process (Ortega-Gil et al., 2019).
The threshold computed for tissue segmentation was applied to the iodine material
dataset in MARS Vision. The result: no iodine was visualised in the healthy lung
MD, as shown in Figure 4.10c. Concentrations of iodine above this threshold visu-
alised in the TB-infected lung were associated with diseased tissue, and specifically,
helped locate TB lesions. Figure 4.10c and 4.10d illustrated, using the magic lens





Figure 4.10: Visualisation of micro-CT energy data of healthy lung (a) and TB-infected
lung (b), and MARS MD data of healthy lung (c) and TB-infected lung (d). The MARS
MD colour bar displays iodine concentration. Water, lipid, and energy data is not shown.
4.3.2.1 Tissue analysis
Table 4.2 presents the segmentation thresholds, whereby the volume of voxels belong-
ing to each window provided sample volumes in mm3. Due to whole organ uptake,
iodine concentration was normalised to 0 mg/mL by considering the threshold of
healthy and background for MARS MD images.
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Table 4.2: Thresholds for tissue segmentation by HU for micro-CT and iodine concentra-
tion for MARS imaging.
MARS spectral CT (mg/mL) SuperArgus micro-CT (HU)
Background < 0 < - 70
Healthy tissue 0 < 24.4 < 5% margin < 25.52 -70 < 2803 < 5% margin < 2943
TB-related tissue 25.52 < 36.2 2943 < 3096
The healthy lung volume was quantified: 44.6 mm3 and 49.7 mm3 for MARS
imaging and micro-CT, respectively. The TB-infected lung was quantified: healthy
tissue was found to be 35.3 mm3 and 43.8 mm3 for MARS imaging and micro-CT,
respectively. The volume of disease related tissue was found to be 5.79 mm3 and 0.88
mm3 for MARS imaging and micro-CT, respectively. For micro-CT, the 5% margin
employed was established in previous research (Ortega-Gil et al., 2019). For the
MD information, only one healthy lung dataset was available. Multiple MD datasets
from different samples would enable statistically relevant margins for MARS material
images, which could minimise the difference in diseased tissue volume measured by
MARS MD and micro-CT. The current study was a proof-of-concept, thus multiple
samples were not scanned.
4.4 Discussion
Bacteria-specific imaging is an active area of preclinical research with encouraging
results. The goal is to provide non-invasive whole-body analysis using bacteria-
specific imaging probes. Patient outcomes could be significantly improved by fast
identification of infection and monitoring of disease response to treatment. Sev-
eral radio-labelled derivatives of antibiotics for PET imaging have been investigated
(Mutch et al., 2018; Ordonez et al., 2017; Z. Zhang et al., 2018). Again for PET, the
selective metabolism of small molecules, such as sugar, for differentiating bacterial
infections from noninfectious processes has been examined (Ordonez et al., 2017).
Key biomarkers and drugs specific to TB labelled with high-Z atoms, used in con-
junction with spectral photon-counting imaging, could enable a more sensitive and
specific probe, and provide valuable information on disease severity and drug deliv-
ery. The potential utility of functionalised or labelled nanoparticles is demonstrated
in Chapters 5 and 6.
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Results of the current ex-vivo study showed cutting-edge spectral CT imaging
can locate and measure two non-specific contrast materials taken up by TB lesions.
The study compared contrast material uptake in TB-infected versus healthy ex-
cised mouse lungs, using two imaging modalities. MARS imaging can accurately
distinguish iodine, silver, soft-tissue like, and fat-like material, simultaneously. The
total volume of the healthy lung quantified by the SuperArgus micro-CT energy
images were similar to that quantified by the MARS scanner energy and material
images. However, tissue segmentation within the TB diseased lung showed differ-
ences in quantification. A 5% margin was applied to the threshold between healthy
and diseased tissue for both the micro-CT and MARS-MD results. The margin
was established by previous research using energy-integrating data (Ortega-Gil et
al., 2019). For more accurate and statistically relevant thresholds and margins for
MARS images, multiple MD datasets to show multiple iodine identification within
samples would be necessary. However, the proof-of-concept study was successful
in illustrating the ability of MARS spectral CT to distinguish multiple materials
simultaneously and the possible utility of MARS in infectious disease.
With regards to drug development, translational research using preclinical CT
systems play a pivotal role in the management of TB, by assessing disease sever-
ity and evaluating new effective anti-tuberculosis drug combinations for therapy
(P. L. Lin et al., 2013; Ortega-Gil et al., 2018; Via et al., 2012). CT offers high reso-
lution, low cost, and wide availability. Intensity histograms in Hounsfield Units are
used to provide tissue characterisation, since diseased tissue present abnormal den-
sities in the organ of interest (Lalwani et al., 2013; Ortega-Gil et al., 2018, 2019).
Soft-tissue imaging, however, is limited, and characterisation of abnormal X-ray
densities associated with TB is highly challenging in preclinical research due to the
ground-glass opacity of TB lesions (Jeong & Lee, 2008; Khan et al., 1977; K. S. Lee,
Hwang, Chung, Kim, & Kwon, 1996; Perlman et al., 1997; Van Dyck, Vanhoenacker,
Van den Brande, & De Schepper, 2003; Woodring et al., 1986). Contrast material
can be employed to enhance attenuation and assist in 3D visualisation of soft tissue
and lesion composition (Metscher, 2009).
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Another potential advantage of translational spectral imaging includes the re-
duction of biological variability (each animal is utilised as its own control), acquiring
data non-invasively, repeated imaging if needed, and a reduction in the number of
animals required for a particular study (Allport & Weissleder, 2001; Cunha et al.,
2014). When live animal imaging is implemented on the MARS research scanner,
longitudinal quantitative imaging data can be collected from the same animal, and
subtle functional changes and development of structural changes over time can be
identified (Peterson et al., 2011). With regards to MARS TB imaging, future studies
would benefit from investigating the comparison of contrast uptake in TB lesions
versus non-TB lung masses. This would demonstrate the ability to distinguish TB
lesions from non-TB nodules, using spectral CT. More precise diagnosis, monitoring
of therapy efficacy, and the development of new and more effective drugs is key to
the eradication of TB.
4.5 Summary
• The current experiments were carried out in excised mouse lungs and revealed
promising results that support the potential utility of spectral imaging for
infectious diseases with non-specific, commonly used contrast material.
• MARS energy resolution enabled accurate differentiation of two high-Z mate-
rials with small differences in atomic number.
• Volume of TB-related tissue differed for micro-CT and MARS imaging. This
may be due to the margin employed. Multiple samples of MD information
could enable a statistically relevant margin.
• In the future, spectral photon-counting imaging of live animals could allow
longitudinal monitoring of disease progression, and real-time observation of
vaccine and drug efficacy.
• TB-specific ligand, antibody, or drug functionalised with high-Z material, for
instance gold nanoparticles, could be used in conjunction with spectral photon-
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Quantitative imaging of monoclonal
antibody functionalised gold
nanoparticles targeted to breast and
lymphoma cancer - an in-vitro study
The current chapter describes an in-vitro study which demonstrated that spectral
photon-counting imaging, using the MARS scanner, can measure gold nanoparticle
labelled specific antibodies targeted to specific cancer cells. Functional nanoparticles
can be integrated with spectral CT to generate a combined diagnostic imaging and
a therapeutic agent which can be detected and monitored. Breast cancer was chosen
as a representative candidate to show the proof-of-concept imaging study. Since this
technique achieved its potential, the technique could be applied to other cancers, as
shown using the Raji cancer cell line. The image data was acquired prior to the be-
ginning of my Ph.D. However, I assisted in analysis to ensure the response obtained
was consistent. The outcome of this study included the publication; Moghiseh et al.
(2018), which I am equal first author and corresponding author, and was a stepping




Breast cancer is the most common cancer in women, and the second most occurring
cancer overall (Ferlay, Héry, Autier, & Sankaranarayanan, 2010; Lilyquist, Ruddy,
Vachon, & Couch, 2018). Steps involved in breast cancer treatment are determined
by the clinical diagnosis of the tumour site. Typical diagnostic techniques are mam-
mography, ultrasound, MRI and/or biopsy (Weber et al., 2008). The failures as-
sociated with breast cancer treatment are often due to the inability of traditional
diagnostic techniques to detect pathological and/or physiological changes at the
cancer site, known as tumour heterogeneity. The progressing tumour heterogene-
ity indicates the coexistence of sub-populations of cancer cells that differ in ge-
netic, phenotypic, or behavioural characteristics within a primary tumour, leading
to metastasis of breast cancer (Meacham & Morrison, 2013). In addition, only
62% of patients with localised breast cancer (before metastasis occurs) can be di-
agnosed using current technologies; meaning one third of individuals with breast
cancer go undiagnosed until metastasis occurs. The 5-year survival rate of a women
with metastatic breast cancer is 27% (American Society of Clinical Oncology, n.d.).
These statistics call for an urgent need to design and develop a new technique for
active targeting of breast cancer heterogeneity for more effective diagnosis and per-
sonalised therapy.
The over expression of human epidermal growth factor receptor (HER2) plays
an important role in cell growth and differentiation. HER2 is a prominent breast
cancer biomarker (receptor on breast cells) which has an association with higher
growth and spread rate compared to HER2 negative breast cancer cells (Hicks et
al., 2017). HER2 gene amplification, a reported range of 20% to 30% of invasive
breast cancers, results in an over-expression of HER2 (Buckley et al., 2016) and is
referred to as HER2 positive. Since the HER2 positive breast cancer biomarker is
associated with a more aggressive disease, the biomarker therefore has a significant
bearing on prognosis and outcome (Ross et al., 2009). According to research, the
HER2 expression status can vary within the primary tumour, metastasis, and/or
throughout the treatment process (Yeung et al., 2016).
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To treat HER2 positive breast cancer, targeted therapy using trastuzumab (Her-
ceptin) has been developed (Ross et al., 2009; Swain et al., 2015, 2013). Herceptin
is a humanised monoclonal antibody directed against the extracellular domain of
HER2. According to a study by Perez et al. (2014) with 4,046 patients with HER2
positive status, with the addition of herceptin therapy, the relative improvement
in overall survival was improved by 37% (hazard ratio, 0.63; 95% CI, 0.54 to 0.73;
P <.001) and an increase in 10-year overall survival rate from 75.2% to 84% was
observed. Reported by I. Smith (2001), the inclusion of herceptin as a chemother-
apy drug resulted in an increase in survival time, slower rate of disease progression,
and an increase in response rate. The study also confirmed that the beneficial
characteristics were more prominent in patients with higher levels of HER2 expres-
sion (Cohen, 2015). However, as mentioned, the heterogeneous expression of HER2
suggests that some patients are less likely to benefit from herceptin therapy and an
alternative treatment may be necessary to target HER2 negative breast cancer cells.
Currently, HER2 positive status is assessed by the collection of core tissue biopsy
from the breast cancer tumour. Laboratory analysis of the tissue samples is per-
formed using immunohistochemistry, which measures the amount of HER2 protein,
or fluorescence in situ hybridisation, which looks at HER2 gene amplification in the
tumour cells (Canadian Cancer Society, 2019). Biopsies are required because cur-
rent clinical imaging modalities remain unable to assess tumour heterogeneity due
to technical limitations (Weber et al., 2008). However, as discussed in Chapter 4,
biopsies are an invasive procedure and only provide a localised indication of tumour
heterogeneity (they do not report on the entire tumour mass). As a result, HER2
status may be left undetected which may result in poorer patient outcomes.
The current chapter reports the first MARS imaging of herceptin modified AuNPs
specific to HER2 positive breast cancer cells. The purpose of this study was to
show a novel multifunctional platform that enables the simultaneous identification
of heterogeneity and assessment of treatment. To support the current studies proof-
of-concept, a second batch of AuNPs were modified with monoclonal antibody and
anti-cancer drug: rituximab, which is specific to Raji lymphoma cancer cells (CD20
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positive human B-cell line). In addition, the Raji cancer cell line and rituximab
modified AuNPs demonstrated the study concept can be applied to different cancer
types, and provided a cross-over experiment. A negative control is an ideal scenario
for a pre-clinical proof-of-concept which shows the ability of MARS technology to
distinguish and quantify specifically labelled cells.
5.2 Materials and methods
Sections 5.2.1 to 5.2.3 are methods performed by collaborator Dr John Goodwyn
Lewis, Ph.D, from the Department of Steroid and Immunobiochemistry Laboratory,
Christchurch, New Zealand. Details in these sections provide the reader with basic
understanding of cell and nanoparticle preparation for MARS imaging. Refer to the
manuscript Moghiseh et al. (2018) for methodology and results of the enzyme-linked
immunosorbent assay (ELISA) studies, AuNP characterisation, and antibodies and
labelling. These studies provide related information but were beyond the scope of
the current chapter.
5.2.1 Cell lines
The HER2 positive human breast cancer line SKBR3 and the CD20 positive human
B-cell line Raji were obtained from frozen stocks held by the Steroid & Immunobio-
chemistry Laboratory, Canterbury Health Laboratories, Christchurch, New Zealand.
Cell-based ELISA experiments were performed on the two cell lines by a collabora-
tor, Dr John Lewis, at the University of Otago, Christchurch. ELISA was used to
optimise incubation and labelling conditions for subsequent labelling with antibody-
AuNPs and analysis by spectral CT scanning.
In addition, the use of both SKBR3 and Raji cells enabled cross-over control
experiments for each monoclonal antibody as SKBR3 is HER2 positive, whilst Raji
cells are CD20 positive but HER2 negative.
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5.2.2 Functionalisation of gold nanoparticles
The streptavidin modified (Avvakumova et al., 2018) gold nanoparticles (AuNPs)
of size 40 nm were purchased from Fitzgerald Industries, Acton, MA, USA. Char-
acterisation was performed by UV-Visible spectrophotometry and dynamic light
scattering (Malvern Nano Zetasizer ZS) to confirm the material, size, and size dis-
tribution. The absorption spectrum of AuNPs caused by surface plasmon absorption
is directly related to the nanoparticle size. surface plasmon resonance (SPR) is the
coherent excitation of all free electrons within the conduction band. As particle size
increases, the wavelength of SPR related to absorption shifts to longer, redder wave-
lengths (Kumar, Meenan, & Dixon, 2012; Zhao & Feng, 2014). SPR is important
as it allows the AuNP size to be identified as the gold added to the experiment.
The AuNPs were functionalised by attaching antibodies. Herceptin (trastuzumab,
Roche Pharmaceuticals, Mississauga, ON, Canada) binds exclusively to HER2 pos-
itive human breast cancer cells and rituximab (Mabthera, Roche Pharmaceuticals,
Mississauga, ON, Canada) binds to CD20 antigen on human B-cell lymphomas.
Both drugs are humanised chimeric therapeutic monoclonal antibodies with a human
Fc domain. Goat anti-human IgGFc-biotin was sourced from Fitzgerald Industries,
Acton, MA, USA. Streptavidin-peroxidase was supplied by Jackson Immunoresearch
Laboratories, West Grove, PA, USA.
5.2.3 Gold labelling of cells
SKBR3 (20-100 million) and Raji (20-100 million) cells were harvested, washed, and
each cell type divided into two portions. Each portion was incubated with either
herceptin or rituximab (1:100 of 2 mg/mL in phosphate buffered saline (PBS) con-
taining 1% fetal calf serum (FCS)) for 30 minutes at 20oC in 1.5 mL Eppendorf tubes
and continually mixed. The cells were then washed and anti-human IgGFc-biotin
(1:100 in PBS containing 1% FCS) was added for 30 minutes at 20oC. Following
three washes in PBS, streptavidin-Au was added (1:10 in PBS containing 1% FCS)
for a further 30 minutes at 20oC. Finally, the cells were washed three times in PBS
and transferred to 0.5 mL Eppendorf tubes and pelleted for MARS scanning.
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5.2.4 MARS imaging
A 200 µL Eppendorf vial of SKBR3 incubated with herceptin gold nanoparticle
complex (Her-AuNPs) was placed in a PMMA phantom holder along with a vial of
SKBR3 incubated with rituximab gold nanoparticle complex (Rit-AuNPs) as con-
trol. In a separate PMMA phantom holder, Raji lymphoma cells were treated with
the same protocol, incubated with Her-AuNPs and Rit-AuNPs. Water, lipid, and
aqueous Au solutions (2, 4, and 8 mg/mL) were used for calibration purposes in
both phantoms (see fig. 5.1).
The summary of the scanning protocol is presented in Table 5.1. Acquired data
was reconstructed in four CSM energy bins (18-30, 30-45, 45-75, 75-118 keV). The
mass attenuation coefficients were obtained from analysis of the AuCl calibration
vials using an in-house program. MD was applied to the energy images and herceptin
and rituximab functionalised AuNPs were quantified within the cell using MARS
Vision.
(a) SKBR3 cell phantom (b) Raji cell phantom
Figure 5.1: (a) 200 µL Eppendorf tubes containing calibration material and vials of
SKBR3 cell line and AuNP complex, placed in a PMMA phantom holder. (b) Similarly,
Raji cell phantom contains calibration material and two Raji cell vials.
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Table 5.1: Raji and SKBR3 imaging protocol for scanning with MARS-11 (V5.1 (2016)
S/N:11).
Protocol parameters
Scan type Continuous motion
Tube voltage 18 kVp
Tube current 12 µA
Exposure time 300 ms
SDD, SOD 250 mm, 200 mm
Field of view 38 mm
Circular projections over 360o 720
Flat-fields 720
Voxel size (isotropic) 0.1 mm
X-ray filtration 3.8 mm Al (2 mm Al + 1.8 mm Al intrinsic)
Energy thresholds 18, 30, 45, 75keV




Key findings include streptavidin modified AuNPs of size 40 nm showed the lambda
max peak at 530 nm which confirms nanoparticle size, cell-based ELISA studies
for the Raji cell line showed higher responses with rituximab dilutions of anti-
human IgG-biotin and streptavidin-peroxidase compared to the same dilutions of
biotinylated-rituximab and streptavidin peroxidase, and similarly, cell-based ELISA
studies on the HER2 cell line showed higher responses with the herceptin dilutions
of antihuman IgGFc-biotin and streptavidin-peroxidase compared to biotinylated-
herceptin and streptavidin-peroxidase. Thus, the former combination (anti-human
IgG-biotin and streptavidin-peroxidase), with the addition of streptavidin-Au was
selected, with the rationale that this combination would provide a higher gold pay-
load for spectral photon-counting CT imaging. Refer to Moghiseh et al. (2018) for
full results of the ELISA studies and gold nanoparticle characterisation.
5.3.1 MARS imaging
Figure 5.2 shows the reconstructed images of the Raji cell phantom in each energy
bin (indicated). The attenuation signal in HUs as a function of concentration data
has been included in Figure 5.3a. Furthermore, the spectral response of the detec-
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tor obtained from the Au vials in the Raji phantom was plotted in Figure 5.3b.
Considering the K-edge of gold to be 80.7 keV, as expected, an enhancement of at-
tenuation in energy bin 4 (75-118 keV) for each concentration of AuCl was observed.
For the cell vials, attenuation comes from a combination of cell material, or
soft tissue, and gold. Combining a low concentration of gold relative to soft tissue
results in the K-edge of gold being hidden or masked by the response produced by
the soft tissue. Thus, the K-edge of gold is not obvious in the energy information
(HUs). However, gold material was still detected, a phenomenon which is described
by Bateman et al. (2015) where it was shown that the K-edge can be recovered
through basis decomposition. Greater HU was observed for Raji cells with Rit-
AuNPs and SKBR3 with Her-AuNPs, as shown in Figure 5.3c and Figure 5.3d,
respectively. By only observing the spectral response of the detector, spectral CT
imaging can indicate the presence of an attenuating material; the gold attached to
herceptin. Thus, showing herceptin uptake into the SKBR3 cells, and rituximab
uptake into Raji cells.
Figure 5.2: MARS energy images of the Raji cell phantom detailed in Figure 5.1b. All




Figure 5.3: (a) Linearity of attenuation of AuCl calibration vials for each energy bin:
R2 = 0.99 for all bins. (b) Spectral response of the detector for AuCl calibration vials.
Enhancement of attenuation due to Au K-edge observed in energy bin four (75-118 keV).
Inserts show material decomposed images corresponding to each concentration. (c) and
(d) display the spectral response of Raji and SKBR3 cells, respectively. Standard error
shown for spectral response data.
Using MD, Figure 5.4 illustrates the detection of AuNPs in the calibration vials
(a)-(c), study cells (d) and (f), and control cells (e) and (g). The concentration
of Au measured from the MD (see fig. 5.4) for each calibration vial was plotted
against the actual concentration, the resulting plot achieved an R2 value of 0.999.
Quantification of the cell vials was performed and the results displayed in Figure
5.5. A significantly lower amount (mg) of Au was detected and quantified in the
control cells; meaning five-fold lower gold was measured in the SKBR3 cells in-
cubated with rituximab modified AuNPs compared to SKBR3 cells incubated with
herceptin modified AuNPs, and Raji cells incubated with herceptin modified AuNPs
compared to Raji cells incubated with rituximab modified AuNPs.
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(a) (b) (c) (d) (e) (f) (g)
Figure 5.4: 2D volumetric visualisation of material decomposed Au (gold/orange) and en-
ergy information (grey). (a) Au 8mg/m L, (b) 4mg/mL, (c) 2mg/mL, (d) study: Raji cells
plus rituximab-AuNPs (e) control: Raji cells plus herceptin-AuNPs, (f) study: SKBR3
cells plus Her-AuNPs, (g) control: SKBR3 cells plus Rit-AuNPs.
(a) (b)
Figure 5.5: (a) Measured amount of targeted and non-targeted AuNPs (mg) within
SKBR3 quantified from MD images displayed. (b) Measured amount of targeted and
non-targeted AuNPs (mg) within Raji cells calculated from MD images. Inserts show
Raji cells plus Rit-AuNPs and Raji cells plus Her-AuNPs.
5.4 Discussion
The key outcomes of the current in-vitro study were two-fold; first, the study
demonstrated that spectral photon-counting imaging, achieved with the MARS scan-
ner, can measure gold labelled specific antibodies targeted to specific cancer cells;
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and second, that functional nanoparticles can be integrated with spectral photon-
counting CT to generate a combined diagnostic imaging technique and a therapeutic
agent.
Medical imaging is key to the diagnosis and assessment of disease response in
many areas of medicine. However, the measurement of disease activity, host re-
sponse, and the effectiveness of treatment is frequently slow and indirect, unless
invasive quantitative procedures are performed. The concepts of using AuNPs with
biotin to deliver a drug is well known (Heo et al., 2012). Rituximab has been deliv-
ered using AuNPs (Fan, Lou, Zhang, & Gu, 2014) and herceptin delivered by indium
radio-labelled AuNPs which has been shown to be cytotoxic in-vitro (Z. Cai et al.,
2016). The use of biotin and streptavidin with antibodies to target HER2 positive
tumours is an established method (Wartlick et al., 2004). In the current study,
SKBR3, a breast cancer cell line which over-expresses HER2, and herceptin mono-
clonal antibody were used to test both the molecular specific binding of function-
alised AuNPs and spectral CT imaging. Utilising these established methodologies,
findings from the study demonstrated the proof-of-concept that spectral CT imaging
can identify and quantify specific monoclonal antibody-labelled AuNPs taken up by
Raji cells and HER2 positive SKBR3 breast cancer cells.
Herceptin works by attaching to HER2 on the cancer cells and inhibiting in-
tracellular signalling. A cross-over experiment was conducted to further support
the study proof-of-concept. Rituximab, a monoclonal antibody which destroys both
normal and malignant B-cells that have CD20 receptors on their surface, is used to
treat diseases that have over-expressed or dysfunctional B-cells; for instance, Raji
cells. The MARS scanner was used to differentiate gold, water, and lipid. Estab-
lishing linearity of attenuation in each energy bin created multiple monochromatic
CTs from a polychromatic CT X-ray source (Weber et al., 2008). Accurate linearity
of the system for a given material (R2 values ≈ 0.99 for all four energy bins were
established) validated the quantification of that material using MD information.
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5.4. Discussion
The current non-specific imaging approach to cancer management, where the
cancer is re-imaged to assess tumour size, or PET is performed to see if the metabolic
activity has reduced, implying treatment is working, could be transformed by photon-
counting imaging. Furthermore, target-specific probes are a crucial aspect for the
development of diagnostic and therapeutic methods that address personalised treat-
ment. The focus of treatment becomes the individual patient rather than the dis-
ease (Mansi, Cuccurullo, & Grassi, 2016). Moreover, current pathological methods
to assess biopsy and whole breast specimens are unable to determine tumour het-
erogeneity, mostly because the specimen has to be cut into sections and sampled.
Heterogeneity can be under-reported or missed due to sampling errors. Therefore,
the current study may also pave the way towards providing a new approach to char-
acterise breast cancer cell types within the specimens. Multiple targeted markers
used in conjunction with spectral photon-counting CT could map out and specifi-
cally identify the different populations of breast cancer cells (or different cancer cells
in case of different tumour types) within the specimen – identifying and measuring
cancer heterogeneity.
5.4.1 Conclusion
The results from the current study establish the proof-of-concept that spectral
photon-counting CT imaging, in conjunction with target-specific/functionalised AuNPs,
can provide valuable information on tumour heterogeneity and drug delivery. The
current study has the potential to have a major impact on the management of can-
cers that express specific biomarkers, such as the expression of HER2. Analysis of
the cell line energy data reported a spectral response that, although did not present
an enhancement in attenuation in the fourth energy bin, indicated the presence
of attenuating material. During the course of data analysis, the hidden K-edge
phenomenon was observed. The MARS-MD algorithm was able to recover the hid-
den information using the effective linear attenuation for each material (for each
concentration and energy bin) which was estimated by taking the mean of the re-
spective regions in the reconstructed data, ultimately, demonstrating the uniqueness
of spectral CT imaging (Raja et al., 2018). Moreover, since the current study was
conducted, MARS scanners have developed significantly. MARS scanners presently
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operate with larger cameras and improved software, providing a larger FOV and
significantly reduced scanning times. Thus, the next step would be performing live
in-vivo mouse imaging of a breast cancer model to measure tumour heterogeneity
with functionalised nanoparticles and, if the tumour is treated, assess response to
treatment.
5.5 Summary
• AuNPs show promise for multifunctional imaging and drug delivery applica-
tions.
• In-vitro methodology that aimed to measure gold labelled specific monoclonal
antibodies targeted to specific cancer cells was successfully established.
• Herceptin and rituximab were shown to target HER2 positive SKBR3 breast
cancer and Raji B-cell lymphoma, respectively.
• A key issue that was observed and fulfilled during the study was to load optimal
amounts of AuNPs for quantitative analysis using spectral CT.
• The information provided is relevant for the development of more sensitive and
specific diagnostics for various malignancies using functionalised nanoparticles.
• Spectral photon-counting imaging has the potential to allow accurate diagnosis
of tumour type, size, and location.
• The next step is performing live in-vivo mouse imaging of a breast cancer
model.
• The methodology in the current study was designed to translate to human
imaging so that in the future, tumour heterogeneity can be detected and treat-








contrast - an ex-vivo and in-vivo
study
The current chapter describes two proof-of-concept studies involving energy-resolving
spectral CT imaging of hafnia-based nanoparticle contrast. Firstly, nitrilotriacetic
acid (NTA) functionalised sub-5 nm hafnia nanoparticles (HfNPs) targeted to bone
microdamage was investigated in an ex-vivo human phalanx sample and in-vivo
rat specimens. Secondly, bio-functionalised HfNPs delivered by oral gavage were
imaged in-vivo for visualisation of the gastrointestinal (GI) tract. These proof-of-
concept studies demonstrated the utility of molecular CT imaging in detecting and
quantifying functionalised HfNP contrast (ex-vivo and in-vivo), and in helping to
develop novel functionalised nanoparticle-based contrast materials. My contribution
included MARS imaging protocol design, data acquisition, image processing and in-
terpretation, and write up. Furthermore, the outcome of this work included the
publication Ostadhossein et al. (2020), and a manuscript submitted for publication
to Nanoscale Horizons, titled: “Hitchhiking probiotic vectors to deliver ultra-small
hafnia nanoparticles for color gastrointestinal tract photon-counting X-ray imaging”





Bone material is self-repairing and is capable of operating under conditions of high
loading, stress, and strain. In addition, bone microdamages are essential for re-
modelling to maintain bone integrity. Cyclic stresses are known to cause fatigue
microcracks, which are quickly detected and repaired by the body (D. Taylor, Hazen-
berg, & Lee, 2007). However, the repair process can be suppressed by drugs (Burr,
2002), genetics (Tsuji et al., 2006), age (Gaston & Simpson, 2007), or bone disor-
ders (Acevedo, Stadelmann, Pioletti, Alliston, & Ritchie, 2018). Deficient repair can
lead to bone failure in the form of fractures due to the accumulation of unrepaired
damage. The risk of crack propagation and fracture drastically increases with age
and bone conditions, such as osteoporosis (Acevedo et al., 2018; Zioupos, 2001).
Characterisation and diagnosis of bone microdamages is essential for estimating the
fractures and fragility risk factors in order to conduct appropriate and timely in-
tervention (Lambers, Kuhn, & Müller, 2012). A consequence of late diagnosis is
observed in the statistics describing hip fractures, which are associated with the
greatest morbidity and up to 20% mortality within six months (Riggs & Melton Iii,
1995). Furthermore, research by Melton Iii (1996) suggests the incidence of hip
fractures worldwide will increase from 1.7 million, recorded in 1990, to 6.3 million
by 2050.
Microdamages are discontinuities in the calcium-rich bone matrix at the microm-
eter range (parallel to the bone’s longitudinal axis ≈ 400 µm and perpendicular ≈
100 µm) (D. Taylor et al., 2007). Detection of microdamage has been achieved by
a wide range of techniques including X-ray (Morris, 1968), scanning electron mi-
croscope (Chamay & Tschantz, 1972), and reflected photomicrography (Carter &
Hayes, 1977). More recently, acoustic emission (Zioupos, Currey, & Sedman, 1994)
and Raman spectroscopy (Henry, Sharma, Cardinal, Kurouski, & Van Duyne, 2016;
Jiang, Wang, Wang, Song, & Lu, 2017; Timlin, Carden, Morris, Rajachar, & Kohn,
2000) have been used in research to identify bone microdamages. The aforemen-
tioned imaging techniques (except standard X-ray) all rely on histological sections,
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thus, are highly invasive, often destructive, only provide 2D information, and not
possible for in-vivo studies (Lee et al., 2003). PET is capable of detecting regions of
microdamage in-vivo using a sodium fluoride tracer. However, limitations of PET
are low resolution and uptake of the tracer is not specific to bone microdamages,
rather cellular activity in close proximity to microdamage (Li, Miller, Hutchins, &
Burr, 2005). Finally, non-specific contrast such as iodine-based (Lee et al., 2003;
Parkesh, Lee, Gunnlaugsson, & Gowin, 2006), lead sulfide (Tang & Vashishth, 2007),
and barium sulfate contrast (X. Wang, Masse, et al., 2007), have been investigated
using micro-CT. However, micro-CT is not translatable to human imaging, and
targeted nanoparticle contrast is advantageous over non-targeted or non-specific
contrast.
Photon-counting CT has the potential to provide non-invasive, high resolution
imaging of bone microdamage. The current study investigated targeted nanoparticle
contrast and photon-counting CT imaging as a way of non-invasively detecting and
measuring bone microdamages. The targeted contrast utilised was ligand-modified
sub-5 nm hafnium oxide (hafnia: HfO2) nanoparticles (HfNPs) targeted to bone
microdamage. At the site of damage, breaks in the HA matrix exposes new surfaces
and freshly charged ions on the new surfaces. In 1 µm3 volume of compact bone,
calcium ions make up 55% of the ions present (Lee et al., 2003). The functionalised
HfNPs work by binding to the calcium ions with the introduction of NTA, a chelating
agent (Ostadhossein et al., 2020). Detection of the high-Z material, Hf, is possible
with standard CT imaging (Lee et al., 2003); however, attenuation by bone material
can cause beam hardening (selective attenuation of lower energy photons) or photon
starvation artifacts (insufficient photons reach the detector due to a high attenuating
material) (Ostadhossein et al., 2020). Further, spatial resolution of standard CT (≈
500-625 µm due to larger pixel size) cannot detect damage on the micrometer scale
(Lin & Alessio, 2009). The photon-counting small pixel detectors within the MARS
scanners offer a suitable technique for high resolution molecular imaging, especially
when used in conjunction with suitable contrast material (previously demonstrated
in Chapters 4 and 5).
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6.1. Introduction
Previous research has reported that Hf provides superior overall performance at
clinical X-ray energy range in comparison to other commonly researched CT contrast
agents, such as iodine, bismuth, and gold (McGinnity et al., 2016; Nowak, Hupfer,
Brauweiler, Eisa, & Kalender, 2011). That is, Hf in nanoparticle form possesses
unique attenuation characteristics ideal for spectral X-ray imaging, with a K-edge
(65.5 keV) that falls close to the middle of the diagnostic energy range. Moreover,
HfNPs are currently under clinical trial as a radio-sensitiser for soft tissue sarcoma,
head and neck, liver, prostate, and rectal cancers, which implies relative safety of
their use for human applications (Bonvalot et al., 2018; Le Tourneau et al., 2018;
P. Zhang, Vivet, Paris, & Pottier, 2017). Therefore, as contrast materials continue
to develop, such as those seen with Hf-based nanoparticles, high resolution spectral
CT could provide a non-invasive and sensitive assessment of bone microdamages,
enabling quick, accurate diagnosis and improved patient outcomes (see fig. 6.1).
The physico-chemical properties and nanoparticle integrity was confirmed by in-
vitro target specific binding by Ostadhossein et al. (2020). The results revealed a
seven-fold higher binding for targeted HfNPs compared to the non-targeted HfNPs.
The results verified the potential of functionalised HfNPs for effective binding to the
major bone component at a site of microdamage. Moreover, HfNPs have been shown
to be biocompatible, and due to their small size of 4 nm (after polymer coating and
targeted agent attached), are excreted safely through the reticuloendothelial system
(Ostadhossein et al., 2020). The current study demonstrated the binding potential
of HfNPs ex-vivo in excised human phalanx and in-vivo in Sprague Dawley rat
specimens, imaged using the MARS research scanners.
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Figure 6.1: Schematic illustrating the work flow for MD of bone, soft tissue (water), and
microdamage for unequivocal diagnosis (Hf). Photon-counting CT is used to detect signal
generated by HfNPs bound to the hard tissue of bone both in the ev vivo model and
in-vivo. The magic lens tool is used to highlight Hf in MARS MD. The diagram of the
mass attenuation coefficient curves for Hf, soft-tissue equivalent, and hydrogen is shown,
extracted from NIST database. Image credit: Ostadhossein et al. (2020).
6.1.2 GI tract
Gastrointestinal (GI) diseases can involve tissue from the oesophagus to the rectum.
Chronic GI diseases can lead to poor quality of life, and in acute cases, contribute
to a shortened lifespan/increased mortality. Early detection of such disorders are
essential for accurate diagnosis and timely treatment management. Direct visuali-
sation of the GI tract can be achieved via endoscopy or colonoscopy (Gilja et al.,
2007), however, these procedures are highly invasive and can cause severe discom-
fort to the patient and possible intestinal perforation in an already vulnerable GI
system (Park, Choi, Jung, & Kim, 2016). Furthermore, endoscopy techniques fail to
provide visualisation of the deeper wall layers and surrounding tissues. Non-invasive
imaging methods for visualisation of the GI tract include MRI, ultrasound, multide-
tector CT (MDCT), and conventional radiography. As previously mentioned, MRI
provides excellent soft tissue imaging, however, has much higher financial and time
cost compared to CT. Ultrasound is capable of high soft tissue resolution with no
ionising radiation. A key disadvantage of ultrasound is poor image quality due to
intestinal gases. MDCT is energy-integrating, which has been discussed in detail in
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Chapter 2. Refer to Frøkjær, Drewes, and Gregersen (2009) for a full discussion of
advantages and disadvantages associated with imaging methods and visualisation
of the GI tract. Energy-resolving CT provides high resolution and the potential to
image the entire GI tract.
Almost all noninvasive imaging examinations of the GI tract require ingestible
contrast to distinguish abnormal tissue from normal tissue. Contrast material is used
despite risk of renal and hypersensitivity toxicity (McDonald et al., 2016; Solomon
& Dauerman, 2010). Reducing contrast toxicity is a constant area of research, as
described in Chapter 1. The current study was an investigation of the detection of
novel bio-functionalised HfNPs within the GI tract imaging, using MARS imaging.
The aim of using biologically modified nanoparticles was to prevent leaching and
degradation of the nanoparticles inside the GI tract (Akin et al., 2007; Dobrovolskaia
& McNeil, 2007; Fang, Kroll, Gao, & Zhang, 2018; Felfoul et al., 2016; Goldberg
& Gomez-Orellana, 2003; Mahmoudi, Bertrand, Zope, & Farokhzad, 2016). Ultra-
small (sub-5 nm) HfNPs were delivered by non-virulent probiotic strains. Probiotics
have the ability to colonise the human GI tract and have been reported to have
beneficial effects for several GI disorders, such as inflammatory bowel disease and
enteric infection (Danino et al., 2015; Suez, Zmora, Segal, & Elinav, 2019).
6.2 Bone microdamage
6.2.1 Materials and methods
Sections 6.2.1.1 to 6.2.1.3 are materials and methods performed by collaborator Dr
Dipanjan Pan (PhD, Department of Bioengineering, Urbana, IL, USA and Depart-
ments of Chemical, Biochemical, and Environmental Engineering and Diagnostic
Radiology and Nuclear Medicine, University of Maryland, MD, USA) and Fatemeh
Ostadhossein (PhD student, Department of Bioengineering, University of Illinois,
Urbana, IL, USA). Details in these sections provide related information, for exam-
ple, the basic understanding of HfNP synthesis and sample preparation. Refer to the
manuscript Ostadhossein et al. (2020) for full methodology and results of nanopar-
ticle synthesis, characterisation, and biocompatibility studies.
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Whole animal experiments were carried out in accordance to the ethical guide-
lines outlined by the Illinois Institutional Animal Care and Use Committee at the
University of Illinois Urbana Champaign. Procedures were approved by the board
(protocol #17125).
6.2.1.1 Synthesis of functionalised HfNPs for bone microcrack targeting
HfNPs were synthesised via a base catalysed sol-gel water-in-oil micro-emulsion
method and stepwise silane reactions (Ostadhossein et al., 2020). Surface chem-
istry of the nanoparticles (exposed amines) provided easy modification, and thus
functionalisation, with surface molecule NTA. NTA is an amino-carboxylic, multi-
dentate ligand, which forms coordination compounds with metal ions such as Ca2+,
Co2+, and Fe3+ (Barnett & Uchtman, 1979). An amino group was covalently bonded
to the non targeted nanoparticles. An affinity for Ca2+ binding leads to an accumu-
lation of HfNPs at locations in the body with a high Ca2+ ion content, for instance
at the site of bone microcracks (Ostadhossein et al., 2020).
Nanoparticle characterisation was performed by transmission electron microscopy
(TEM), electrophoretic ζ-potential, proton nuclear magnetic resonance spectra (1H
NMR), and Fourier transform infrared spectroscopy (FTIR) to confirm material
and NTA conjunction, nanoparticle size, and size distribution (Ostadhossein et al.,
2020).
6.2.1.2 Labelling of excised human phalanx bone
Evidence of the binding of HfNPs was demonstrated in an ex-vivo experiment using
an excised human phalanx. Surface microdamage was surgically induced using a
scalpel, which exposed mineral phase calcium ions. Labelling was achieved by incu-
bating the bone sample in 2 mL of targeted HfNP water solution (30 mg/mL) for
24 hours. Following incubation, the bone sample was washed with water to remove
any excess/unbound nanoparticles. The sample was fixed in an agarose gel (1 wt%),
which appears as soft-tissue under X-ray.
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Three samples of excised human phalanx were scanned using Xradia Bio Mi-
croCT (MicroXCT-400): 1) no microdamage, 2) induced microdamage and in-
cubated in targeted HfNPs, and 3) induced microdamage and incubated in non-
targeted HfNPs.
6.2.1.3 In-vivo animal specimen preparation
Motivated by the outcomes of the ex-vivo human bone experiment, an in-vivo model
of bone microdamage was investigated for a proof-of-concept study. The model used
was a simplistic representation of external bone microdamage and included targeted
and non-targeted nanoparticle injected Sprague Dawley rats (Kim et al., 2018). The
animals were anaesthetised using a gas mixture of isoflurane and oxygen. Fur on
the left hind limb was removed and an incision was made (' 1 cm long) to reveal
the adductor longus and gracilis muscles. The tibia bone was identified, dehydrated
by ethanol, and microdamage induced longitudinally using a surgical scalpel. The
microdamage measured approximately 1-2 cm long and 0.2 cm deep. The right hind
limb was left intact and served as a healthy comparison. Following suturing of the
surgical site, 100 µL of either targeted or non-targeted HfNPs were injected intra-
muscularly into the muscle surrounding the tibia. The surgical site was sterilised
and the pain managed by applying sterile gas, iodophor, and injecting carprofen (1.5
mg/kg, SC) at regular intervals until euthanasia of the animal was performed 5 hrs
post-injection.
One control animal (no microdamage) and four animals with artificially in-
duced microdamage and either targeted or non-targeted HfNPs injected were imaged
with conventional General Electric Speed 16-slice CT system (GE, Milwaukee, WI,
USA). Image post-processing of all samples was achieved using 3D Slicer software
(www.slicer.org). The scanning parameters utilised included: slice thickness: 0.625




The scanning protocol was first designed using a phantom that contained HfNP so-
lution (1.25, 2.5, 5, 10, 20, 40 mg/mL), clinical contrast, iohexol (20, 40, 80 mg/mL),
lipid, and water. Analysis of NIST data considered the K-edges of hafnium (65.4
keV) and iodine (33.3 keV). The final CSM energy thresholds were selected to be 30,
45, 65, and 80 keV (refer to Chapter 2, Section 2.2.1). MARS-MD was applied to
the phantom and material identification and quantification assessment performed:
results are presented in Appendix B.1. The final biological sample calibration phan-
tom contained 200 µL Eppendorf vials of aqueous targeted HfNP solution of vary-
ing concentrations (2.5, 5, 10, 20, 40 mg/mL), HA rods (HA50, 100, 200, 400, 600
g/cm3), water, and lipid, as shown in Figure 6.2a. To prevent precipitation of the
HfNP vials, a vortex mixer was employed prior to scanning.
Following protocol optimisation and scanning of the calibration phantom, the fol-
lowing biological samples were scanned with the MARS scanner: (1) excised human
phalanx incubated in targeted HfNPs and (2) two rats with surgically induced bone
microdamage, injected with either targeted or non-targeted HfNPs and euthanised
five hours post-injection. All samples were frozen during transportation, however,
were thawed prior to scanning. Figure 6.3 shows a rat specimen secured within a
custom-holder in preparation for a MARS scan.
(a) (b)
Figure 6.2: (a) PMMA calibration phantom with 200 µL Eppendorf PCR tubes containing
aqueous HfNP solution of various concentrations, HA rods, water, and lipid. Eight tubes
were placed around the periphery and 4 within the centre. This phantom was employed
for use with MARS-11. (b) Schematic drawing of the calibration phantom.
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Figure 6.3: Female five-month old Sprague Dawley rat prepared for scanning using MARS-
15. The rat is held by a custom-made holder that appears as lipid under X-ray.
MARS-11 (V5.1 (2016) S/N:11) was employed to image the human phalanx sam-
ple. The rat specimens required a larger FOV. Therefore, MARS-15 (V5.2 (2017)
S/N:15) operating a five-chip camera was utilised to enable a larger FOV whilst
simultaneously reducing scan time. Summary of the scanning protocols for MARS-
11 and MARS-15 are presented in Table 6.1. The MARS-15 protocol was adjusted
to accommodate the larger rat specimen. For example, the FOV was increased to
68 mm (one camera translation). Furthermore, the SDD and SOD were increased
to 281.6 mm and 215 mm, respectively. To achieve an equivalent photon count to
MARS-11, the tube current was increased to 25 µA, while the exposure time was
decreased to 150 ms to minimise the scan time. X-ray filtration and energy thresh-
olds remained constant.
Following characterisation of the linearity and spectral response for Hf, HA,
water, and lipid, the basis functions were found and MD was applied to the cali-
bration phantom, ex-vivo human phalanx sample, and in-vivo rat specimens. Four
basis material datasets were acquired: Hf, water, lipid, and HA. MD analysis was
performed by quantifying the measured concentration of the calibration vials, and
MARS vision was used to visualise the material datasets in three-dimensions. Hf
within the targeted and non-targeted nanoparticle injected rats was measured using
the Hf material dataset. In addition, Hf within a region of the stomach (GI tract
contrast study) was measured.
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Table 6.1: Summary of MARS scanner imaging parameters for ex-vivo and in-vivo study.
Protocol parameters MARS-11 MARS-15
Scan type Continuous motion Continuous motion
Tube voltage 118 kVp 118 kVp
Tube current 13 µA 25 µA
Exposure time 300 ms 150 ms
SDD, SOD 250 mm, 250 mm 286.1 mm, 215 mm
Field of view 38 mm 68 mm
Circular projections over 720, 720 720, 720
360o, flat-fields
Voxel size (isotropic) 0.09 mm 0.18 mm
X-ray filtration 3.8 mm Al (2 mm Al + 3.8 mm Al (2 mm Al +
1.8 mm Al intrinsic) 1.8 mm Al intrinsic)
Energy thresholds 30, 45, 65, 80 keV 30, 45, 65, 80 keV
Detector model CZT-Medipic3RX three-chip CZT-Medipic3RX five-chip
6.2.2 Results
Key findings include characterisation of non-targeted HfNPs size using TEM: 4.2 ±
1.1 nm, and electrophoretic ζ-potential and 1H NMR confirmed success of nanopar-
ticle functionalisation with molecule NTA. Refer to Ostadhossein et al. (2020) for
full results of HfNP characterisation.
6.2.2.1 Calibration phantom analysis
Reconstructed images of the calibration phantom for each energy bin are displayed
in Figure 6.4. Precipitation was visible to the naked eye and in the imaging data
in 40 mg/mL HfNP aqueous solution (see fig. 6.5). The region of precipitation was
measured (Hf mg/mL) and was found to increase in concentration at the end of the
scan compared to the start of the scan. An advantage of spectral photon-counting
CT imaging is the ability to image and take measurements of solution precipitation
when or if it occurs. Calibration vial precipitation was addressed by selecting slices
to analyse from the first half of the scan (where the solution appeared most stable)
and avoiding the edge of the vial where precipitation may have occurred.
Attenuation in HU as a function of energy bin is shown for HA and Hf in Fig-
ures 6.6a and 6.6b, respectively. Considering the K-edge of Hf to be 65.4 keV, an
enhancement in attenuation was observed in the third energy bin (60-85 keV) for
each concentration. Furthermore, the attenuation signal in HUs as a function of
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concentration was plotted for Hf and HA in Figures 6.6d and 6.6c, respectively. The
outcome shows the establishment of linearity of attenuation for interpolation of the
concentrations based on the measured HU. The linearity of Hf showed a decrease in
R2 value compared to HA, which is likely due to precipitation.
Figure 6.4: Reconstructed images of the HfNP calibration phantom for each energy bin
(as indicated). Scale bar in HU. The slice shown was selected from the end of the scan
where the PMMA phantom holder is not in view.
Figure 6.5: One axial slice from the Hf material dataset (flipped 90o) viewed in ImageJ
showing the presence of HfNP solution precipitation. Top right: The region of precipitation




Figure 6.6: (a) & (b) Spectral response of the detector for calibration vials. Attenuation
enhancement observed in energy bin 3 (65-80 keV) indicates the K-edge of Hf; 65.4 keV.
The standard errors for each data point are in the range of 1-7 HU. (c) & (d) Linearity
of attenuation of HA and Hf, respectively. The result of the linear regression shows that
the CT system is linear with R2 values indicated on the graph.
The phantom material identification chart is displayed in Figure 6.7. Material
identification success was greater than 99.5% for all densities of HA above 50 g/cm3.
Hf ≥10 mg/mL shows ≥70% material identification success. The concentration of
Hf and HA measured from the MD for each calibration vial was compared to the
actual concentration (see fig. 6.8). The measured and the actual concentration for
Hf and HA correlated well with a linear plot (R2 = 0.99). The error bars for Hf are
5 mg/mL indicating varying concentration due to precipitation. However, the well
correlated linear plot means precipitation occurred at an equal rate for all concen-
trations. An offset could be applied to improve the measured Hf accuracy. MD was
applied to the ex-vivo and in-vivo samples.
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Figure 6.7: Misidentification chart showing lipid (purple), HA (grey), water (blue), and
Hf (green). Densities of HA above 50 mg/cm3 presented greater than 99% successful iden-
tification. For Hf concentrations ≥10 mg/mL, the result is ≥70% successful identification.
Figure 6.8: Measured concentration from MD against the known concentration for Hf and
HA reveal a linear correlation with an R2 value of 0.99. Error bars for HA are in the range
of 1-3 HU.
6.2.2.2 Bone microdamage imaging
Resulting images of three bone specimens acquired by conventional CT are shown
in Figure 6.9a. The bone is highly attenuating, thus resolving Hf signal from bone
proved difficult. Figure 6.9b displays the 3D reconstructed image of the MD infor-
mation which shows HfNPs could be differentiated from bone. The targeted HfNPs
appeared to have selectively bound to freshly exposed calcium ions on the surface of
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the bone microdamage site. Therefore, HfNPs highlighted expected regions of bone
microdamage at high specificity (>70% identification success for ≥10 mg/mL).
Figure 6.9: Micro-CT images and MARS images of the human bone samples with HfNP
contrast.
(a)(i) micro-CT images of the human bone sample with no microdamage (control), (ii)
bone incubated in targeted HfNPs, and (iii) bone incubated in non-targeted HfNPs.
(b) MARS image showing functionalised HfNPs detected at the site of bone microdamage
in excised human bone sample. Hf can be distinguished from bone (white) and soft tissue
(semi-transparent grey), and the signal from Hf can correctly point to the site of damage
(yellow arrows).
Figure 6.10a represents the five Sprague Dawley rats scanned by conventional
CT. Furthermore, 3D reconstruction of the five rats is displayed in Figure 6.10b,
where the signal from HfNP is identified based on HUs (false colour). As is shown
in these images, the animals injected with targeted HfNPs lead to accumulation of
HfNPs adjacent to the bone at 30 minutes. Images acquired five hours post-injection
saw greater accumulation of HfNPs in the bone microdamage site (Ostadhossein et
al., 2020). Regarding non-targeted HfNPs, uptake was observed in the surrounding
muscle in a non-specific manner. Figure 6.10c shows the 3D reconstruction of MD
information of the animal injected with targeted HfNPs euthanised five hours post
injection. Differentiation of soft-tissue, bone, and Hf signal is shown. Quantification
of Hf from the MD information was performed, as shown in Figure 6.11. Results
showed greater targeted HfNP accumulation within the injured limb compared to




Figure 6.10: Conventional CT images and MARS images of the rat specimens with HfNP
contrast.
(a) Microdamage induced by scalpel in the hind limb of a Sprague Dawley rat (i). Con-
ventional CT axial view for control animal (no microdamage) (ii), non-targeted HfNPs
injected and the animal imaged after 30 mins (iii) and five hours (iv). Targeted HfNPs
injected and the animal scanned after 30 mins (v) and five hours (vi).
(b) 3D reconstruction obtained from the conventional CT for control animal (i), non-
targeted HfNPs scanned 30 mins (ii) and five hours post-injection (iii), targeted HfNPs
scanned 30 mins post-injection (iv) and five hours (v). Red arrows indicate attenuation
from HfNPs.
(c) MARS image showing 3D visualisation of functionalised HfNPs detected at the site of
bone microdamage (yellow arrows) in rat specimen. Hf can be distinguished from bone
(white) and soft tissue (semi-transparent grey). Hf concentration is represented by the
colour bar displayed in mg/mL.
(a) (b)
Figure 6.11: Quantification of Hf in the rat hind limbs in the targeted and non-targeted
nanoparticle injected rats. The max concentration found (mg/mL) in the limb and the
total amount (mg) was measured. The values were normalised to the healthy limb of the
same rat, that is, ((value from microdamage limb)-(value from healthy limb)/value from
healthy limb)*100) for each nanoparticle group. Greater accumulation of Hf was observed
for the targeted nanoparticles.
6.3 GI tract imaging
6.3.1 Materials and methods
Sections 6.3.1.1 to 6.3.1.2 are materials and methods performed by collaborator Dr
Dipanjan Pan and Fatemeh Ostadhossein. The same imaging protocol (conventional
CT and MARS) used in bone microdamage imaging was employed for GI tract
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imaging. Refer to Sections 6.2.1.4 and 6.2.1.3 for MARS and conventional CT
scanning protocols, respectively.
6.3.1.1 Synthesis of ultra-small HfNPs for GI tract contrast
Synthesis of the ultra-small HfNPs (≈ 2 nm) was based on nitrate reduction of
Hf containing precursor (Hf nitrate); 3 g of polyvinylpyrrolidone (PVP) and 1 g of
Hf(NO3)4 was dissolved in 100 mL of glycerol and 50 mL of anhydrous ethanol using
a magnetic stir bar at room temperature. NaBH4 (500 mg) was quickly added to
the solution then left for two minutes to allow formation of P-HfNPs. The solu-
tion was centrifuged and washed several times with anhydrous ethanol and water.
Finally, the HfNPs were dried under vacuum (Pan et al., 2010, 2012, 2017). Char-
acterisation was performed by several techniques including transmission electron
microscope (TEM), atomic force microscopy, and UV-Visible spectrophotometry to
confirm shape, size, conjugation, and size distribution.
Two probiotic strains were employed; Escherichia coli; E. coli (nissle) and Lac-
tococcus lactis; L. lactis. The HfNPs (54 mg) were incubated in the two probiotic
types for four hours. TEM and ICP determined the success of HfNP internalisation
into the bacterial cells.
6.3.1.2 In-vivo animal specimen preparation
Whole animal experiments were carried out in accordance to the ethical guidelines
outlined by the Illinois Institutional Animal Care and Use Committee at the Uni-
versity of Illinois Urbana Champaign. The procedures were approved by the board
(protocol #17125).
The bio-HfNPs were resuspended in 1 mL of PBS and then administered via oral
gavage to one healthy five-month-old female Sprague Dawley rat. After 30 minutes,




A key finding was the TEM characterisation of the nanoparticles which indicated
the ultra-small HfNPs were well-dispersed and spherical, with size distribution of
2.13 ± 0.52 nm (Manuscript submitted for publication: (Ostadhossein et al., Under
review)).
6.3.2.1 GI tract imaging
Bone and HfNPs are highly attenuating material, therefore, both appear bright in
the image. The HfNP material data enabled the differentiation of bone and hafnia,
as shown in Figure 6.12a and 6.12b (arrows indicate hafnia and bone-like material).
3D visualisation of MD information is displayed in Figure 6.12c, which gives a clear
indication of the uptake of bio-functionalised HfNPs. Location of the accumulation
of HfNPs was validated by data obtained by conventional CT, as shown in Figure
6.13. The intestine, caecum, and small bowel were lit up by the HfNPs. In addition,
the Hf contrast was detected elsewhere apart from the internal organs, indicating
systemic uptake of the ultra-small HfNPs. Thus, the HfNPs were detected in highly
vascularised regions within the animal, such as the hind limbs and skull. Five hours
gave time for the HfNPs to be taken up systemically. If the animal had not been
euthanised, the HfNPs would have gone on to be cleared by the reticuloendothelial
system. Moreover, the concentration of HfNPs within the circled region in Figure
6.12c was measured, providing a quantitative assessment of nanoparticle delivery.
Hf concentration within the region of interest ranged between 2.8 and 447 mg/mL.
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Figure 6.12: (a) Coronal view from one CSM energy bin of the rat for GI tract imaging
of orally administered probiotics incubated with HfNPs. The energy image shows a bright
area within the stomach region (yellow arrow), which has similar HU value to bone (white
arrow). (b) Coronal view with Hf material channel overlay the energy bin channel. The
bright area is associated with the presence of Hf solution according to MD information.
MD enables differentiation of Hf, bone, and soft tissue. (c) 3D volumetric visualisation of
the rat MD from the energy data obtained from the MARS scanner. The region within
the stomach that suggests a high presence of Hf is magnified (insert) and circled.
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Figure 6.13: 3D visualisation of information obtained from conventional CT imaging show-
ing HfNPs accumulation in rat specimen. HfNPs were observed in the internal organs:
caecum, small intestine, rectum, and anus.
6.4 Discussion
The current chapter showed novel spectral photon-counting imaging of HfNPs for
two applications using the MARS scanner. The first application involved targeted la-
belling of bone microdamage ex-vivo and in-vivo. Quantitative assessment revealed
the ratio of HfNP uptake within the damaged limb and healthy limb (of the same
rat) increased for targeted HfNPs compared to non-targeted HfNPs: a 258% increase
in total Hf (mg) and 27% increase in max Hf concentration (mg/mL) was mea-
sured. The clinical gold standard for quantitative assessment of bone health relies
on transmitted light microscopy (TLM) using stains, such as fluorochromes specific
to bone minerals (Burr & Hooser, 1995; Burr & Stafford, 1990; Haupert, Guerard,
Peyrin, Mitton, & Laugier, 2014). TLM relies on thin histological sections, which
are invasive, destructive, and only provide 2D information. Non-invasive imaging
currently available that is capable of assessing bone microdamage directly is high
energy, monochromatic synchrotron radiation (Nalla, Stölken, Kinney, & Ritchie,
2005). However, synchrotron imaging is not readily accessible or capable of imaging
large numbers of tissue samples, relatively large in size (Zhang, Ross, & Roeder,
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2010). In contrast, biocompatible, targeted contrast and spectral CT could enable
non-invasive characterisation and diagnosis of bone microdamage, which is essential
for estimating the fracture and fragility risk factors.
The second application involved HfNP contrast packed inside probiotics for orally
delivered contrast for GI tract imaging. 3D rendering of the spectral information
showed the stomach and proximal and distal regions of the small intestine were
highlighted by the contrast. The results revealed that probiotic modified HfNPs
enabled the hafnia-based contrast to withstand the harsh environment of the GI
tract. Compared to other commonly researched CT contrasts, hafnia provides supe-
rior overall performance at the clinical X-ray energy range (McGinnity et al., 2016;
Nowak et al., 2011). HfNPs contrast has the potential to be a patient-friendly, oral
contrast for the examination of various digestive system disorders. micro-CT and
conventional CT were also used to show the presence of HfNPs within the excised
human phalanx and animal samples, respectively. Results from these modalities
supported the results obtained by MARS imaging. Time constraints precluded the
use of histology in the current chapter. However, histological validation is included
in a manuscript submitted for publication (Ostadhossein et al., Under review).
6.4.1 Limitations and future direction
MARS-11 possessed a three-chip camera when the studies reported in the current
chapter were conducted. Chapter 3 outlined my contribution to the commissioning
of MARS-11 following installation of the three-chip camera. The scanner was able
to be leased for experimental studies post commissioning, as quality stability of the
scanner was assessed. However, a key issue for MARS-11 was the three-chip camera
which was not suitable for larger specimens, due to the increased scan time and
limited FOV. Therefore, MARS-11 was only used to image the calibration phantom
and bone specimen, whilst MARS-15 (five-chip camera) was utilised for rat speci-
men imaging. Thus, there is potential for inter-machine variability. Future studies
would benefit from performing image quality stability assessments of MARS-15, and
comparing the results to MARS-11. Carrying out scans of the calibration phantom
and bone using MARS-15 would also enable evaluation of inter-machine variability.
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Smaller nanoparticles are at higher risk of aggregation compared to larger nanopar-
ticles (Lamberti et al., 2014). Thus, a challenge faced when imaging ultra-small
nanoparticles is solution stability. In future, for such situations where precipitation
occurs, post processing software could incorporate an offset which would result in
the measured concentration equalling the actual concentration. Moreover, if mod-
ifications to the HfNP contrast were made to improve solution stability, spectral
photon-counting imaging could be used to determine if the modifications made were
appropriate. In the future, modifications and improvements to novel contrasts could
be assessed quantitatively and non-invasively in-vitro, ex-vivo, and in-vivo, using the
MARS scanner. The implication is that MARS imaging can aid in the development
of novel contrasts to improve specificity, toxicity, and ultimately, diagnosis and treat-
ment outcomes.
Intramuscular delivery of the HfNPs into the surrounding muscle of the injured
limb (bone microdamage study) meant the hind limbs were not treated equally.
Future studies would benefit from (1) imaging a rat with no microdamage but with
nanoparticles injected in the same area; (2) investigation of different methods of
delivery, such as intravascular; and, (3) investigation of the differentiation of hafina
and iohexol in-vivo, since this has been demonstrated in a phantom already (see
Appendix B.1). Finally, the current chapter was a proof-of-concept study, therefore
the number of animals examined was reduced. When live imaging is implemented on
the MARS research scanner, a larger number of animals could be utilised to provide
statistically relevant data. In addition, longitudinal quantitative imaging data could
be collected from the same animal (Peterson et al., 2011).
6.4.2 Conclusion
Iodine and AuNPs are the most prominently used contrast materials in clinical
diagnostic imaging and research, respectively (McGinnity et al., 2016). Iodine-
based contrast was imaged ex-vivo in Chapter 4 and AuNPs imaged in-vitro in
Chapter 5. In the current study, Hf in nanoparticle form was modified to target bone
microdamage and to be used as an ingestible contrast. The outcomes of the current
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study support the results achieved in Chapter 5; that is, functional nanoparticles can
be integrated with spectral CT to generate a diagnostic probe with high specificity.
The development of more sensitive and specific probes can be applied to various
diseases, such as infectious disease, cancer, GI, and bone disorders. Ultimately,
personalised medicine and improved treatment outcomes could be made possible.
6.5 Summary
• HfNPs show promise for targeted imaging of bone microcracks.
• In-vivo methodology that aimed to detect and measure bone microdamage
labelled by hafnia was successfully established.
• Targeted and non-targeted HfNPs were quantified within the injured limb; the
total accumulation (mg) was greater for targeted nanoparticles compared to
non-targeted nanoparticles.
• A key issue that could be addressed in future studies is the method of deliv-
ery. Investigation of NPs delivered via intravascular injection or intramuscular
away from the site of injury would treat each hind limb equally, allowing for
a limb to be used as a control.
• In the future, methodology established in the current chapter could be used
in a live animal model of bone microdamage to assess microdamage over time
in the same animal.
• HfNPs packed within probiotics show promise for a patient-friendly, orally
administered CT contrast for non-invasive examination of the GI tract. In-vivo
methodology that aimed to “light up” the GI tract by hafnia was successfully
established.
• Bio-functionalised HfNPs withstood the harsh environment of the GI tract
and highlighted details of the GI tract.
• The MARS spectral CT scanning protocol could be optimised to favour mate-
rial identification of Hf signal in future studies. This would improve linearity
of attenuation and thus reduce misidentification at all concentrations of Hf.
104
• MARS imaging has the potential to aid in the development of functionalised
nanoparticles by quantifying delivery of nanoparticles non-invasively.
• The development of more sensitive and specific probes can be applied to var-
ious diseases, such as infectious disease, cancer, GI, and bone disorders. Ul-






Conclusion and future direction
7.1 Final remarks
The current thesis comprises original work demonstrating molecular imaging using
a MARS spectral scanner. The significance of photon-counting spectral CT and the
characteristics that make high-Z nanoparticles ideal for contrast-enhanced molecular
imaging were discussed in Chapter 1. Chapter 2 provided prerequisite information
regarding the development of CT imaging, MD, and preclinical challenges. Chapter
3 investigated image quality stability following an upgrade to the MARS-11 research
scanner, located at the University of Otago, Christchurch campus. The scanner was
then commissioned for use for biological experiments. The major findings of this
PhD are outlined in the following sections.
In Chapter 4, four CSM energy bins provided sufficient spectral information for
the simultaneous differentiation of iodine and silver. In an ex-vivo mouse model
of chronic TB, identification of iodine contrast enabled segmentation and volume
quantification of healthy and disease-related lung tissue. The results demonstrated
the potential clinical utility of photon-counting CT imaging for molecular imaging in
infectious lung diseases. In the future, if a TB-specific drug were to be incorporated
with a high-Z nanoparticle, MARS scanners could provide non-invasive evaluation
of drug delivery and response to treatment. Such an imaging platform would have
the potential to assist diagnosis and accelerate the development of novel therapies,
which is essential for the eradication of TB.
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In the second study (Chapter 5), the MARS scanner was used to evaluate two
functionalised nanoparticle contrasts. Gold nanoparticles were functionalised with
herceptin or rituximab. Herceptin and rituximab are well known monoclonal an-
tibodies used in treatment therapies for breast (herceptin) and lymphoma cancer
(rituximab). The results showed photon-counting CT was capable of performing
molecular imaging by identifying and quantifying cellular uptake of the gold la-
belled antibodies in-vitro. Thus, MARS imaging addresses the issue of assessing
whole tumour heterogeneity using functionalised nanoparticle contrast. The impli-
cation of non-invasive evaluation of whole tumour heterogeneity is the potential of
personalised medicine. Management of cancers and other diseases that express spe-
cific biomarkers can be differentiated from surrounding tissues at high resolution.
The focus of treatment is shifted from the disease to the individual patient. Fur-
thermore, as tumour heterogeneity can change over the course of treatment, therapy
can be adjusted accordingly. Ultimately, personalised medicine will lead to improved
treatment outcomes for patients with cancer.
The development of novel contrasts for molecular imaging were reported in
Chapters 4 and 5. To further this development, novel functionalised hafnia-based
nanoparticle contrasts were utilised in Chapter 6. The potential clinical applica-
tions assessed were bone microdamage and GI tract imaging using the hafnia-based
contrasts. MARS imaging evaluated the performance of the functionalised nanopar-
ticles by materially separating hafnium, bone, and soft tissue in-vivo. This study has
two important implications; the first relates to highlighting bone microcracks non-
invasively using targeted contrast. In the future, photon-counting CT imaging could
be used to identify microcracks before they lead to fractures or permanent damage.
The second key implication relates to GI tract imaging, whereby MARS images
showed that bio-functionalised hafnia nanoparticles avoided degradation inside the
GI tract. In this instance, future use of bio-functionalised hafnia nanoparticles could
be a patient-friendly, ingestible contrast for GI tract imaging.
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To conclude, the results presented in the current thesis support the idea that
photon-counting CT imaging is capable of molecular imaging when enhanced by
high-Z pharmaceuticals. Functionalised nanoparticle contrasts were shown to have
greater diagnostic value compared to their non-functionalised counterparts. More-
over, the implications of combining diagnostic and therapeutic function (theranos-
tics) are increased sensitivity and specificity leading to more personalised medicine.
There is potential for the development of targeted contrast material for use with
photon-counting CT imaging in a range of diseases. The current thesis demon-
strated successful applications involving infectious disease, cancer, GI tract visuali-
sation, and bone tissue damage.
7.2 Future direction
Photon-counting CT technology promises improved spatial and energy resolution.
Thus, it is clear why photon-counting technology is on the clinical horizon as the
next big step in the evolution of CT. The research in the current thesis has shown
a number of extraordinary future opportunities for photon-counting CT imaging.
Funded by the Government of New Zealand, the MARS Bioimaging project is a
world leader in the manufacturing of small-bore spectral photon-counting CT scan-
ners utilising photon-counting detector technology. MARS Bioimaging is working
towards having point-of-care human MARS imaging systems in hospitals around
New Zealand in the near future. Initially, MARS scanners will be able to conduct
wrist/arm, ankle, and neck scans, with the potential to scan larger areas thereafter.
Figure 7.1 displays the first human images captured by the MARS human scanner
(large-bore) (Panta, Butler, et al., 2018). Furthermore, human clinical trials as-
sessing orthopaedic applications have ethical approval and will begin in mid-2020.
The present thesis is directly relevant to success at the clinical level; without pre-
clinical research, the development of software, hardware, and application method-
ology would not be possible. There is ample opportunity for further experimental
investigations to be conducted, particularly given the continuous advancement of
nanomedicine and spectral imaging.
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Figure 7.1: 3D spectral images of a wrist (with wrist watch) and ankle obtained using
MARS large-bore scanner using a 14-chip camera. Lipid, soft tissue, and bone indicated.
The following section describes possible directions in which future studies could
progress the findings in the current thesis:
• Automation of QA procedures is currently in the works. A possible concept
that could benefit from automation and standardisation is energy threshold
selection. NIST mass attenuation data were used to establish energy thresh-
olds via manual calculations. NIST mass attenuation data do not take into
account a number of crucial parameters, such as scatter effects, filtration, X-
ray tube voltage, tube current, and detector efficiency. Therefore, automation
and standardisation is suggested via a Monte Carlo simulation which could
take into account crucial parameters. Fast and more accurate optimisation of
energy thresholds could be achieved. In the future, several more energy bins in
CSM will be available. This means, user-defined thresholds will no longer be
required, instead, thresholds will be spread equally over the X-ray spectrum.
• Moving towards the clinical translation of high-Z nanoparticle contrasts, efforts
should focus on possible limitations; including (1) physicochemical properties
of nanoparticles for improved cellular internalisation to increase diagnostic
value; (2) evaluation of potential in-vivo toxicity; and (3) the minimum con-
centration that can be administered and detected by MARS scanners.
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• Gold nanoparticles are currently not clinically approved for use in humans.
However, MARS imaging has the potential to significantly contribute to the
efforts of clinically translating high-Z nanoparticles ideal for spectral CT con-
trast. Regarding theranostic agents, binding to cell membranes via surface
receptors can increase circulation time, decrease the dosage administered per
procedure, and reduce the potential pharmaceutical toxicity. Furthermore, the
ability to identify and quantify drug delivery is important in the role of cancer
treatment. In the future, MARS imaging of in-vivo live mouse models could
enable (1) longitudinal monitoring of disease progression and (2) real-time
observation of vaccine and drug delivery and efficacy.
• Another potential clinical application is molecular imaging of atherosclerotic
plaques. The future study could focus on gold nanoparticles targeted to throm-
botic events in atherosclerotic plaque in an in-vivo mouse model. The implica-
tion being spectral molecular imaging will be useful for non-invasive assessment
of vulnerable plaque.
• Multi-parametric analysis and artificial intelligence (AI) could aid in material
analysis and ultimately diagnostic decision making. To achieve accurate AI
software, large amounts of quantitative imaging data must be obtained. There-
fore, data acquired during the course of the current PhD will be further utilised
to contribute to the development of improved software. In the future, AI will
be able to extract meaningful patterns when processing material-specific im-
ages. Integrating spectral CT data with improved, standardised analytical
software will be essential for superior detection of tumour heterogeneity, TB
lesions, and clinical diagnostic decisions for personalised medicine. Currently,
data acquired in Chapter 4 are being utilised to develop an automatic lung
segmentation program that uses both energy and material information.
7.3 Conclusion
To conclude, the long-term goal of providing economic and health benefits to New
Zealand are not that far off. This is evident in the first human photon-counting
CT images produced midway through the current PhD, and in the first human
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clinical trials of spectral CT beginning mid-2020 in Christchurch, New Zealand. In
summary, the current thesis has demonstrated the research and clinical utility of
photon-counting CT imaging using MARS scanners. Personalising and optimising
patient care and outcomes has underpinned this research. The author hopes that
findings from this thesis will contribute to further advancing imaging technologies
with the ultimate goal of improving diagnosis and treatment.
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e Silva, J. M. d. S., Zanette, I., Noël, P. B., Cardoso, M. B., Kimm, M. A., & Pfeiffer,
F. (2015). Three-dimensional non-destructive soft-tissue visualization with X-
ray staining micro-tomography. Scientific Reports , 5 , 14088.
118
Esses, D., Birnbaum, A., Bijur, P., Shah, S., Gleyzer, A., & Gallagher, E. (2004).
Ability of CT to alter decision making in elderly patients with acute abdominal
pain. The American Journal of Emergency Medicine, 22 (4), 270–272.
Evans, D., Workman, A., & Payne, M. (2001). A comparison of the imaging
properties of CCD-based devices used for small field digital mammography.
Physics in Medicine & Biology , 47 (1), 117.
Faby, S., Kuchenbecker, S., Sawall, S., Simons, D., Schlemmer, H.-P., Lell, M., &
Kachelrieß, M. (2015). Performance of today’s dual energy CT and future
multi energy CT in virtual non-contrast imaging and in iodine quantification:
a simulation study. Medical Physics , 42 (7), 4349–4366.
Fan, L., Lou, D., Zhang, Y., & Gu, N. (2014). Rituximab–au nanoprobes for
simultaneous dark-field imaging and DAB staining of CD20 over-expressed on
raji cells. Analyst , 139 (22), 5660–5663.
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018). Cell membrane coating
nanotechnology. Advanced Materials , 30 (23), 1706759.
Felfoul, O., Mohammadi, M., Taherkhani, S., De Lanauze, D., Xu, Y. Z., Loghin, D.,
. . . Gaboury, L. (2016). Magneto-aerotactic bacteria deliver drug-containing
nanoliposomes to tumour hypoxic regions. Nature Nanotechnology , 11 (11),
941.
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Cell line and antibody information
A.1 CD20 positive human B-cell line
Kindly provided by frozen stocks held by the Steroid & Immunobiochemistry Lab-
oratory, Canterbury Health Laboratories, Christchurch, New Zealand.
• Species: Human
• Organ: Lymph
• Disease: B-cell lymphoma
• Growth: Cultured in flasks in RPM1640 supplemented with 10% foetal calf
serum (FCS) media and grown at 37oC in 5% CO2.
• Harvest: Raji cells were harvested during the log phase growth (20-100 mil-
lion), washed, and divided into two portions. Each portion incubated with
either herceptin or rituximab (1:100 of 2mg/mL in PBS containing 1% FCS)
for 30 minutes at 20oC in 1.5mL Eppendorf tubes and continually mixed. The
cells were then washed and antihuman IgGFc-biotin (1:100 in PBS containing
1% FCS) was added for 30 minutes at 20oC. Following three washes in PBS,
streptavidin-Au was added (1:10 in PBS containing 1% FCS) for a further
30 minutes at 20oC. The cells were finally washed three times in PBS and
transferred to 0.5 mL Eppendorf tubes and pelleted for MARS scanning.
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A.2. SKBR3 Cell line
A.2 SKBR3 Cell line
Kindly provided by frozen stocks held by the Steroid & Immunobiochemistry Lab-
oratory, Canterbury Health Laboratories, Christchurch, New Zealand.
• Species: Human
• Organ: Breast
• Disease: HER2 positive human breast cancer
• Growth: Cultured in flasks in RPM1640 supplemented with 10% foetal calf
serum (FCS) media and grown at 37oC in 5% CO2.
• Harvest: SKBR3 cells were harvested at confluence growth. The same methods
of washing, incubating, and pelleting as Raji cells was used.
A.3 Antibody preparation
Rituximab and trastuzumab were dialysed and diluted to 2.5 mg/mL with 0.1M bo-
rate buffer, pH 8.8, 1/20th volume of biotinamidocaproate N hydroxysuccinamide
ester in DMSO (10mg/mL) added (Goat antihuman IgGFc-biotin, Fitzgerald Indus-
tries, Acton, MA), and then mixed for four hours at 20oC. Unreacted biotin ester was
blocked by the addition of 1M ammonium chloride. Following exhaustive dialysis
against phosphate buffered saline (PBS), the material was clarified by centrifugation
and concentration adjusted to 2 mg/mL.
A.4 Cell-based enzyme-link immunosorbent assay
Washed cells were suspended into 11mL of PBS and plated across the wells (100L/well
containing 20,000cells) of a 96well, flat bottomed, microtiter plate. The plate was
centrifuged for 5 minutes to sediment the cells and the PBS was carefully aspirated.
Cells were fixed for 30 minutes at 20oC by adding 2% paraformaldehyde into the
PBS (100L/well). The paraformaldehyde was then carefully aspirated, and the plate
was dried under a gentle stream of air. The plate was then blocked with assay buffer
containing 1% FCS for 30 minutes at 20oC (200 µL/well). Following blocking, the
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buffer was decanted, and the plate was blot dried by inversion. 2 mg/mL dilutions of
either rituximab, trastuzumab, biotinylated rituximab, or biotinylated trastuzumab
were added for 30 minutes at 20oC. The wells were then washed three times (200
L/well). For the rituximab and trastuzumab series, antihuman IgGFc-biotin was
added for another 30 minutes at 20oC (1:1000 in PBS containing 1% FCS and 100
L/well). For the biotinylated rituximab and biotinylated trastuzumab series, the
plates were washed and 100 µL/well of 1:1000 dilution of streptavidin-peroxidase
(Fitzgerald Industries, Acton, MA) (was added for 30 minutes at 20oC, followed by
washing and addition of tetramethylbenzidine substrate (100 µL/well). Following
the addition of antihuman IgGFc-biotin rituximab and herceptin series, the plates
were washed and incubated with 1:1000 streptavidin-peroxidase for 30 minutes at
20oC prior to the final washing and the addition of tetramethylbenzidine substrate
(100 µL/well). Following colour development, the reaction was stopped by the addi-
tion of 1M HCL (100 µL/well) and the absorbency read at 450 nm. The absorption
reading gives an indication of the particle size.
(a) Rituximab dilution (b) Herceptin dilution
Figure A.1: The quantitative data collected using ELISA kit in the form of absorbance
against drug dilution. The collect absorbance reading at 450 nm for (a) rituximab dilution
in the case of Raji cells and (b) herceptin dilution in the case of SKBR3.
The cell-based ELISA studies on the immobilised CD20 positive Raji cell line
showed higher responses with rituximab dilutions and antihuman IgG-biotin and
streptavidin peroxidase compared to the same dilutions of biotinylated-rituximab
and streptavidin peroxidase (open and filled circles, respectively), A.1a. Similarly,
cell-based ELISA studies on immobilized confluent HER2 positive human breast
cancer cells (SKBR3) showed higher responses with the herceptin, antihuman IgGFc-
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A.4. Cell-based enzyme-link immunosorbent assay
biotin and streptavidin-peroxidase combination compared to the biotinylated-herceptin
and streptavidin-peroxidase combination (open and closed triangles respectively),
A.1b. The trastuzumab and rituximab controls are also shown in A.1 and show
that the two antibodies can clearly be distinguished in a cross-over study. Hence,
for the current study, the former combination, with the addition of streptavidin-Au
in the final step, was chosen with the rationale that this combination would provide a
higher gold payload for scanning. Indeed, we confirmed this rationale by small scale




Chapter 6 imaged HfNPs in two different applications. The final phantom is shown in
Figure 6.2. Prior to this phantom, a brief experiment was carried out with the aim
to differentiate hafnium and iodine signal. Two different protocols with different
X-ray filtrations were tested. The optimal filtration was found to be aluminium.
The phantom contained HfNP solution (1.25, 2.5, 5, 10, 20, 40 mg/mL), clinical
contrast, iohexol (20, 40, 80 mg/mL), lipid, and water. Analysis of NIST data,
which considered the K-edge of Hf (65.4 keV) and iodine (33.3 keV), the CSM
energy thresholds were selected: 30, 45, 65, and 80 keV. MARS-MD was applied to
the phantom and material identification and quantification assessment performed.
The resulting energy information and MD information are displayed in Figures B.1
and B.2, respectively. Quantification assessment is shown in Figure B.3.
Figure B.1: Axial slice of the phantom containing iohexol, hafnia nanoparticles, and lipid,
in four energy bins. X-ray attenuation of each voxel is shown in HU.
145
Figure B.2: (a) i-iv shows each material dataset separately. (b) 3D visualisation of the
phantom material decomposition with material datasets fused. The signal from Hf, lipid,
air, water, and iodine can be separated using MARS-MD, enabling colour quantitative
assessment of Hf nanoparticles in the aqueous solution.
(a) (b)
Figure B.3: Hafnium and iodine plotted with linear trend fitted. R2 percentage of the
response variable variation that is explained by a linear model shown. Quantification of
Hf was less accurate, compared to iohexol. This was likely due to precipitation. For
calibration of the biological samples, a vortex mixer will be used immediately prior to
scanning, and slices for analysis carefully selected.
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